OasisLMS

Regular Abstract

Case Series

P01.01 This is a test title

EP.01.01 Exercise Training Modalities in Patients With Lung Cancer: A Protocol for Systematic Review and Network Meta-Analysis

EP.01.02 Long-Term Survival After Curative Surgery for Stage I-III NSCLC Patients in British Columbia, 2005-2021: A Population-Based Study

EP.01.03 Young Patients With Non-Small Cell Lung Cancer in Poland - a Comprehensive Epidemiological, Molecular and Prognostic Analysis

EP.01.04 Features, Demographics and Treatment Profiles of Primary Lung Cancer Cases in Nigeria: The Largest Single Centre Report in West Africa

EP.01.05 Mapping the Clinical Pathways in Lung Cancer: Evaluating the Inspire Program in the Brazilian Public Healthcare System

EP.01.06 Clinical Characteristics, Molecular Profile and Survival Outcomes in Young Lung Cancer Patients From Western India

EP.01.07 Lung Cancer in Young: A Descriptive Study From Thoracic Oncology Clinic in Northern India

EP.01.08 Lung Cancer in Elderly Patients: Insights From a Community Oncology Setting in Western India

EP.01.09 NSCLC Epidemiology and Survival in Denmark, Finland, and Norway: A Decade of Real-World Insights From the LANDSCAPE Study

EP.01.10 Young Onset Lung Cancer: Clinical, Pathologic and Molecular Profile From a Tertiary Care Centre in India

EP.01.11 Impact of Demographics and Smoking on Driver Gene Mutations Development in Non-Small Cell Lung Cancer (NSCLC)

EP.01.12 A Causal Machine Learning Approach for the Prediction of Immune-Related Adverse Events in Lung Cancer Patients Receiving Immunotherapy

EP.01.13 Lung Cancer Burden in Latin America and the Caribbean, 1990-2021: A Comprehensive Analysis

EP.01.14 Pulmonary Pure Ground-Glass Nodule Follow-Up During Pregnancy and Lactation: A Case Report

EP.01.15 Gender Disparities in Survival Outcomes of “Minimally Invasive Lung Squamous Cell Carcinoma”

EP.01.16 Differential Effect of Neoadjuvant Therapy in Locally Advanced Non-Small Cell Lung Cancer Based on Sex

EP.01.17 Association Between Cigarette Smoking History and Germline Rare Variant Burden in a Cohort of Lung Cancer Patients

EP.01.18 Family History of Lung Cancer in Lung Cancer in Never-Smokers, a Matched Case-Control Study

EP.01.19 Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study From Greece

EP.01.20 Non-Smoking Lung Adenocarcinoma: Implications for Predominant Growth Patterns, Tumor Heterogeneity and Prognosis

EP.01.21 Mapping Persistent and Irreversible Arsenic Effects on Lung Epithelium Using Integrated Transcriptome and Methylome Analysis

EP.01.22 The Effectiveness of Offering Repeated Co-Located, Opt-Out Smoking Cessation Support Within Lung Cancer Screening

EP.01.23 Tobacco Smoking, Quit Attempts and Vaping Among an Online Sample of South African Cancer Survivors

EP.01.24 Determinants Influencing Smoking Cessation Implementation in an Oncology Setting: Canadian Healthcare Provider Perspectives

EP.01.25 Identifying Effective Strategies to Support Smoking Cessation in Ontario Cancer Care Settings: A Consensus-Building Approach

EP.01.26 Achievements and Future Directions of Tobacco Control in Lung Cancer Prevention in China

EP.01.27 Gender and Tobacco Use Status Shape Support for Endgame Strategies in India

EP.01.28 Changes in Respiratory Function in a Patient Undergoing Two Lung Resections

EP.01.29 Association of the Cholesterol-Modified Prognostic Nutritional Index With the Survival After Lung Resection for Elderly Patients With NSCLC

EP.01.30 Beyond Smoking: Exploring Risk Factors for Lung Cancer in Women

EP.01.31 Vaping, Smoking and Lung Cancer in Adults Under Age 50: A Case-Control Study

EP.02.01 Investigating the MET Exon 14 Interactome in Lung Adenocarcinoma

EP.02.02 YB-1 Is a Survival Factor for Mesothelioma-Associated Fibroblasts

EP.02.03 Investigating the Therapeutic Potential of DUSP4/6 Inhibition in Lung Adenocarcinoma

EP.02.04 Identification of a Novel Immunotherapy Target in EGFR-Mutant Lung Cancer Resistant to Immune Checkpoint Inhibitors

EP.02.05 Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method

EP.02.06 Natural Multiple Serine Synthase Inhibitors Modulate Tumor Microenvironment Polarization and Inhibit the Growth of Lung Cancer

EP.02.07 Enhancing Alectinib Efficacy in ALKPositive Non-Small Cell Lung Cancer by Targeting Mtor

EP.02.08 Exploratory Effect of Cisplatin on Autophagic Pathway in Human Lung Adenocarcinoma Cell Line

EP.02.09 Deciphering CD47-Mediated Platelet-Tumor Crosstalk and Its Role in NSCLC Metastasis

EP.02.10 Fumarate and Ass1 in KRAS-Mutant NSCLC: The Influence of Cetuximab in Combination With KRAS G12C Inhibitors (Sotorasib and Fulzerasib)

EP.02.11 Clinical and Biological Significance of Cystathionine Gamma-Lyase in Pulmonary Adenocarcinoma

EP02.12 Identifying Acquired Resistance Mechanisms to Sotorasib in G12C Lung Adenocarcinoma (LuAD) Cell Lines (CL)

EP.03.01 Identification and Validation of Recurrence-Associated Proteins in Stage I Lung Adenocarcinoma

EP.03.02 An Integrating Multiomic Approach to Chart the Tumor Immune Microenvironment Associated to Immunotherapy Response in Non-Small Cell Lung Cancer

EP.03.03 Tumor Heterogeneity Consisting of SCLC With RB1 Exon 19 Deletion and L718V Mutation-Positive Adenocarcinoma in EGFR-TKI Resistant Lung Cancer

EP.03.04 PD-L1-Regulated c-Met Phosphorylation Contributes to MET Amplification in EGFR Mutation NSCLC

EP.03.05 The Study on the Mechanism of OM-85 in Regulating the Immune Microenvironment in Early-Stage Lung Adenocarcinoma

EP.03.06 Blocking JNK Signaling as a Strategy to Fight EGFR-Driven Lung Cancer

EP.03.07 The Role of Tumour Intrinsic Inflammasome Mutations in Lung Adenocarcinoma

EP.03.08 Tumor Treating Fields (TTFields) Concomitant With Antiangiogenic Therapy in Non-Small Cell Lung Cancer in Vivo Model

EP.03.09 A New Treatment Approach for Non-Small Cell Lung Cancer

EP.03.10 Evaluating the Role of the Blood-Brain Barrier in Intracranial Response Rates for Metastatic Lung Cancer

EP.03.11 Peritumoral B Lymphocyte Mediated Immune Response Is Associated With Survival in Patients With Non-Small Cell Lung Cancer

EP.03.12 Sex-Specific Blood-Based Immune Signatures Predict Response to First-Line Immunotherapy in Advanced NSCLC: A Prospective Translational Study

EP.03.13 LIF Is Associated With Poor Prognosis and Participates in Lung Cancer Growth and Implantation in Preclinical Models of NSCLC

EP.03.14 Single-Cell Transcriptome Analysis Revealed an Activated Tumor Immune Microenvironment in KRAS Mutant NSCLC

EP.03.15 Chemotherapy Upregulates PD-L1 Expression via cGAS-STING Pathway in Non-Small Cell Lung Cancer

EP.03.16 Cell-Specific Fluorescence Lifetime Values in Live Non-Small Cell Lung Cancer Cells

EP.03.17 Altered Immune Profile in Lung Cancer Patients With Pneumonitis

EP.04.01 Current Status of Lung Cancer Screening in Latin America

EP.04.02 Fully-Automated Classification of Parenchymal Low Attenuation-Clusters as Indicators of Pulmonary Emphysema in Lung Cancer Screening

EP.04.03 Uptake and Impact of a Framework to Support Implementation of Low-Dose Computed Tomography (LDCT) Screening for Lung Cancer

EP.04.04 A Relative Perspective on Whether Risk-Based Lung Screening Eligibility Prioritize People With Higher Competing Mortality

EP.04.05 Lung Cancer Diagnosis Among Screening Participants in the Multi-Health-System Philadelphia Lung Cancer Learning Community

EP.04.06 Health Beliefs and Adherence to Lung Cancer Screening in a Diverse, Real-World Population

EP.04.07 Participant and Provider Experiences in an Indigenous Focused Trial of Lung Cancer Screening in Aotearoa New Zealand

EP.04.08 Building Policy Recommendations Using an Implementation Framework for Low-Dose Computed Tomography Screening

EP.04.09 Identifying Drivers of Racial and Ethnic Disparities in Lung Cancer Screening Initiation After Clinician Referral

EP.04.10 Evaluating Primary Care Practice’s LCS Smoking History Accuracy for Maori Patients - Implications for a Future Lung Cancer Screening Programme

EP.04.11 Feasibility of AI-Assisted Mobile Low-Dose CT Screening in Underserved Communities in China

EP.04.12 Outcome of Lung RADS Category 4 in Lung Cancer Screening Population at Tertiary Hospital, Single Center Study

EP.04.13 Emphysema on Baseline CT Predicts Copd and Cardiovascular Death After 25 Years in Lung Cancer Screening

EP.04.14 Pilot Lung Cancer Screening Program and "Lung Health Check" in Lleida: Preliminary Results

EP.04.15 Determinants of Lung Cancer Screening Intention Among Adults Eligible for Lung Cancer Screening

EP.04.16 Piloting Lung Cancer Screening: Tumor Detection Rate, Psychological Distress and Incidental Findings

EP.04.17 Radiomics Predicts IASLC Grades of Invasive Pulmonary Adenocarcinoma by Distinguishing High-Grade Patterns and Predominant Subtypes

EP.04.18 Preoperative Prediction of Grade 3 Invasive Non-Mucinous Adenocarcinoma Using Semiconductor 18F-FDG-PET/CT: A Diagnostic Accuracy Study

EP.04.19 Radiologic Characteristicsof Solitary Pulmonary Capillary Hemangioma

EP.04.20 Exploring Diffusion-Weighted Magnetic Resonance Imaging in Lung Cancer Screening

EP.04.21 Imaging Manifestations in 4 Cases of Invasive Pulmonary Adenocarcinoma With Indolent Growth

EP.04.22 Internal Validation of the IASTO-PDPI Lung Cancer Risk Level at Indonesia’s National Respiratory Center, Persahabatan Hospital

EP.04.23 Prediction of STAS Positivity in Non-Small Cell Lung Cancer

EP.04.24 Initial Experience With Cancer Screening Center: Model to Improve Lung Cancer Screening Uptake

EP.04.25 Integrated Biological and Imaging Assessment for Pulmonary Nodule Malignancy: A Real-World Study With Large Cohort Modeling and Validation

EP.04.26 A Case Series on Video Fiber Optic Bronchoscopy in the Diagnosis of Non Small Cell Lung Cancer (NSCLC) Subtype: Squamous Cell

EP.04.27 Enhancing Lung Cancer Screening: A Comparative Evaluation of Predictive Models for Malignancy in Pulmonary Nodules

EP.04.28 TD-GC-MS-Based Breath Analysis for Early Diagnosis of Lung Cancer

EP.04.29 Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation

EP.04.30 Second Primary Lung Cancer in Surgically Treated Breast Cancer Patients: Association or Incidental Finding?

EP.04.31 Nomogram for Predicting Lung Cancer-Free Survival in Patients With Persistent Pulmonary Nodules

EP.04.32 The Impact of Symptom Monitoring on Survival Among Patients With Lung Cancer. a 4-Year Follow-Up of the SYMPRO-Lung Study

EP.04.33 Exhaled Breath Analysis Using Infrared Spectroscopy Combined With Machine Learning Algorithms for Lung Cancer Diagnosis

EP.04.34 Preliminary Results of Added Benefit of Blood-Based Biomarkers in a Lung Cancer Screening Program

EP.04.35 Innovative Intraoperative Technique for Rapid Tumor Identification in Lung Cancer Through Spectral Characterization: A Promising Exploration

EP.04.36 Evaluation of the Utility of msignal® for Lung Cancer Screening in a Rural Region of Northern Japan (Hokkaido Region)

EP.04.37 An Observational Study Evaluating the Benefits of AI-Assisted Lung Cancer Screening Using Chest X-Rays in Bangkok, Thailand

EP.04.38 A Computational Framework for Estimating Transportability in Cancer Screening Trials

EP.04.39 Lung Cancer Early Screening via cfDNA Fragmentome Profiling

Detection of Circulating Tumor Cells in Malignant Pleural/Peritoneal Effusions: Applications and Clinical Significance

EP.04.40 Preoperative Prediction of Occult Lymph Node Metastasis in Clinical Stage I NSCLC Using CT Radiomics, PET, and ctDNA

EP.04.41 Detecting Minimal Residual Disease (MRD) in Lung Cancer Using an Epigenetic-Based Liquid Biopsy Approach

EP.04.42 Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research

EP.04.43 Chest X-Ray Analysis With Artificial Intelligence Software Aids in the Early Diagnosis of Lung Cancer- a Case Series

EP.05.01 Use of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Molecular Characterization of Non-Small Cell Lung Cancer

EP.05.02 Evaluation of ROSE Utility in Multiplex Gene-Panel Testing Using Samples From EBUS-GS for Lung Cancer

EP.05.03 Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensionalreconstruction

EP.05.04 SUVmax Predicts Pathologic Complete Response and Survival in Lung Cancer Patients Undergoing Neaodjuvant Treatment

EP.05.05 Invasive Mediastinal Staging of NSCLC Using Vamla: Results and Perspectives

EP.05.06 Should We Screen Patients With Stage IV Non-Small Cell Lung Cancer for Brain Metastases at Diagnosis?

EP.05.07 Prognostic Impact of Double Positive in EGFR Mutation and PD-L1 Expression in Resected pN0M0 G2-3 Adenocarcinoma

EP.05.08 Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging cN0-N1 Non-Small Cell Lung Cancer

EP.06.01 Tumor-Infiltrating Lymphocytes as Predictors of Chemotherapy Response in Non-Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

EP.06.02 Clinical Significance and Preoperative Prediction of High-Grade Subtypes in Early-Stage Lung Adenocarcinoma

EP.06.03 Mucoepidermoid Carcinoma of the Lower Respiratory Tract With Few to None Intermediate/Squamoid Cells: A Challenging Tumor Series

EP.06.04 Extranodal Extension in Lung Adenocarcinoma: Pathological Insights and Its Role as an Independent Prognostic Factor

EP.06.05 Extensive-Stage Small Cell Lung Cancer Compared With Metastatic Extrapulmonary Small Cell Cancers- a Retrospective Study

EP.06.06 Characterization of SMARCA4 and SMARCA2 Alterations in Early-Stage Pulmonary Adenocarcinomas

EP.06.07 Clinicopathologic and Genomic Landscape of Lung Cancer Arising in Interstitial Lung Disease: An Expanded Cohort Analysis

EP.06.08 Mutation Spectrum of EGFR Mutations in South Indian Population Identified by Next Generation Sequencng and Real TIME Pcr

EP.06.09 Integrated Clinical, Radiological and Molecular Profile of Lung Cancer Patients From an Incidental Nodule Detection Program

EP.06.10 Hypoxia-Induced Cancer Stemness, Metastasis, Angiogenesis and Immune Modulation in Lung Adenocarcinoma

EP.06.11 Comprehensive Genomic Profiling in Lung Cancer Management: Insights From North Sweden

EP.06.12 Kita-Kyusyu Lung Cancer Antigen-1 Positive Is Associated With Pathological High-Grade in Lung Adenocarcinoma

EP.06.13 Molecular Alterations in Octogenarians With Early-Stage Lung Cancer: A Real-World Study

EP.06.14 Decreased Expression of DAAM2 Is Correlated With Poor Prognosis and Tumor Immune Microenvironment in Lung Adenocarcinoma

EP.06.15 Reflex Next Generation Sequencing Testing in NSCLC: Overcoming Barriers to Equitable Molecular Profiling in an Urban Healthcare Network ?

EP.06.16 Immunophenotyping of the Molecular Subtypes of Small Cell Lung Cancer and Its Correlation With Prognostic and Therapeutic Implications

EP.06.17 Immunological and Genetic Profile and Efficacy of Immunotherapy in NSCLC Patients With Mutations in KRAS and STK11 Genes

EP.06.18 Is There Any Association Between EGFR Alterations and PD-L1 Expression in NSCLC a Single Center Experience

EP.06.19 The Relationship Between PD-L1 Expression and Tumor Microenvironment in Lung Squamous Cell Carcinoma

EP.06.20 Stage-Dependent Increase in EGFR Mutation Rates in Early-Stage Lung Cancer at National Taiwan University Cancer Center

EP.06.21 Genomic and Demographic Predictors of Survival in Patients With ALK Fusion NSCLC: Insights From a Single-Center Cohort

EP.06.22 Genomic Insights Into ALK-Rearranged NSCLC: A Comprehensive Study

EP.06.23 Comprehensive Genomic Profiling as a Key Determinator in Clinical Staging and Treatment Planning

EP.06.24 Update of Mutation Status and PD-L1 Expression in Lung Cancer

EP.06.25 Analysis of LAT1 Protein Expression and Clinical Characteristics of Patients With Primary Lung Cancer

EP.06.26 Resectable Lung Cancer With KRAS Mutation May Have Less Lymphatic Metastasis

EP.06.27 Challenges in Implementing Targeted Panel NGS for Biomarker Testing in Non-Small Cell Lung Carcinoma in Resource-Constrained Settings

EP.06.28 Circadian CLOCK Expression in Non-Small Cell Lung Cancer

EP.06.29 Prognostic Impact of Lepidic Growth in Intermediate and High-Grade Lung Adenocarcinoma

EP.06.30 Single-Cell RNA Sequencing Reveals a Subset of FSIP1 Cancer Cells and Verified Its Value of Prognosis in Lung Adenocarcinoma

EP.06.31 Prognostic Impact of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Expression in Non-Small Cell Lung Cancer

EP.06.32 Elevated SERPINA3 Expression in Bronchoalveolar Lavage Fluid Predicts Poor Prognosis in Non-Small Cell Lung Cancer

EP.06.33 Unique Features of the Tumor-Microenvironment in PL3 Non-Small Cell Lung Cancer and Their Association With Post-Operative Outcomes

EP.06.34 Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients From Western India

EP.06.35 Role of PD-L1 Expression and TP53Mutation as a Prognostic Factor in Early Stage NSCLC

EP.06.36 Non-Small Cell Lung Cancer With Diffuse Coexpression of TTF-1 and P40:A Clinicopathologic and Molecular Study of 19 Cases

EP.06.37 Clinical and Pathological Features of a High Altitude-Peruvian Population With Metastatic EGFR Mutated Lung Cancer

EP.06.38 HLA-DQB1 Predicts Immunotherapy Response in NSCLC Through Augmented TCR Signaling

EP.06.39 Better Prediction of Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer : Immunoresist Project

EP.06.40 The Role of Histology and Metabolic Parameters in Predicting Spread Through Air Spaces

EP.06.41 CD200 as a Novel Prognostic Biomarker in Early-Stage Lung Adenocarcinoma Immune Microenvironment

EP.06.42 Clinical Characteristics and Treatments of Patients With Advanced Non-Squamous NSCLC KRAS-Mutated With or Without STK11

EP.06.43 Using Artificial Intelligence to Leverage Phenotypic, Genomic and Proteomic Correlations in Lung Carcinoma Patients With MET Alterations

EP.06.44 Tertiary Lymphoid Structures in the Tumor Micro Immune Environment of EGFR Positive Lung Cancer Are Associated Prognosis

EP.06.45 Heterogeneity of Tumor Microenvironment and PD-L1 Expression in NSCLC and Tumor Draining Lymph Nodes After Solid Organ Transplantation

EP.06.46 Frequent Co-Existence of RBM10 Mutation in Patients With Non-Squamous Nsclcs Harboring EGFR Point Mutations

EP.06.47 A Ten-Gene DNA Damage Repair-Related Signature for Predicting Prognosis and Treatment Response in Non-Small Cell Lung Cancer

EP.06.48 Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories

EP.06.49 Analysis of EGFR Mutations Using Highly Sensitive Digital Droplet PCR for EGFR Mutation-Positive NSCLC

EP.06.50 Development of a Novel AI-Augmented Small Cell Lung Cancer (SCLC) Algorithm for Accurately Classifying Cell Types From H&E

EP.06.51 Development of Novel IHC Assay for PD-L1 Detection in Non-Small Cell Lung Cancer

EP.06.52 TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort and Meta-Analysis

EP.06.53 c-MET Expression in Non-Squamous NSCLC: Molecular Correlation and Interobserver and Intersample Concordance on Scoring

EP.06.54 The Landscape of Actionable Genomic Alterations in Non-Small Cell Lung Cancer. A Single Institution Quality Improvement Initiative

EP.06.55 Racial Differences in ERBB2 Mutations in Lung Adenocarcinoma: Insights From a Multi-Cohort Study

EP.06.56 Genomic and Immune Characteristics Linked to Second-Line Combination Immunotherapy Outcome in EGFR-Mutated Advanced NSCLC

EP.06.57 Molecular Analysis of Driver Negative Lung Cancer for Rearrangements and Fusions Using a New HiC Sequencing Assay

EP.06.58 CEACAM5 as a Biomarker for Differentiating Ground-Glass Opacities From Other Lung Cancers

EP.06.59 Dna+RNA-NGS Testing in NSCLC Patients With Primary Resistance to First-Line Non-Targeted Therapy and Negative Driver Genes (Dream Study)

EP.06.60 Exploring the Role of the Oral Microbiome in Saliva Sputum Bronchoalveolar Fluid and Tissue Tumor in Lung Cancer a Systematic Review

EP.06.61 FGRF-2: A Prognostic Biomarker and Potential Therapeutic Target in NSCLC

EP.06.62 Based on Labyrinth Microfluidic Chip in Evaluating Therapeutic Efficacy for Leptomeningeal Metastasis of Lung Cancer

EP.06.63 New Approaches for Enhancing the Efficacy of "Liquid Biopsy" in Non-Small Cell Lung Cancer

EP.06.64 ISET CTC-DNA shows higher sensitivity then ctDNA in early stage lung cancer patients

EP.06.65 Mosaic Chromosomal Alterations and the Risk of Incident Lung Cancer: A Systematic Review and Meta-Analysis

EP.06.66 Prediction of Immune-Related Adverse Events by Human Leukocyte Antigen (HLA) and Other Biomarkers in Patients With Non-Small Cell Lung Cancer

EP.06.67 Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated With HER2 Adc: Preliminary Results From the RESOLUTION Trial

EP.06.68 Clonal Hematopoiesis (CH)-Derived Mutations Detected in Non-Small Cell Lung Cancer (NSCLC) Liquid Biopsies (LBx)

EP.06.69 Real-World Utilization of Tissue-Free ctDNA Monitoring in Patients With Lung Cancer on Targeted Therapies +/- Chemotherapy

EP.06.70 Development and Clinical Application of Ultra-Sensitive Digital EV Assay Targeting GLUT1 for Early Diagnosis of Non-Small Cell Lung Cancer

EP.06.71 Clinical Application of Expert Software Based on Tumor Biomarkers to Stratify Lc-Risk in a Hospital Thoracic Tumor Committee

EP.06.72 Lung Cancer EGFR Mutation Prediction via cfDNA Fragmentome Profiling

EP.06.73 Co-Driver Mutations in Fusion-Positive NSCLC: Liquid Biopsy Insights From 2,369 Patients

EP.06.74 Clinical Validity of Repeated CTCs and CAM-L Enumeration in Treatment Monitoring of Metastatic Non-Small Cell Lung Cancer

EP.06.75 Identifying Emergent Resistance Alterations in Patients With Advanced NSCLC Using Plasma Genotyping (DISCOVER)

EP.06.76 Real-World Use of Tissue-Free ctDNA Monitoring in Patients With Lung Cancer Receiving Immunotherapy And/Or Chemotherapy

EP.06.77 Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-Small Cell Lung Cancer

EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors

EP.06.79 Liquid Biopsy Shortens Time to Diagnosis and Treatment Selection: Primary Results From the International L1St Study

EP.06.80 Immunological Markers of Prognosis in Lung Cancer: T-Cell Subpopulations and Their Correlation With Clinical Outcomes

EP.06.81 Observational Study of Concordance Between Tissue-Based ODxTT CDx and In-House Plasma OPA Gene Analysis in NSCLC Patients

EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib

EP.06.84 Impact of Preoperative Brain Natriuretic Peptide Levels on Postoperative Outcomes in Lung Cancer Patients

EP06.85 Real-World Performance of NGS Panels in Detecting Actionable Genomic Alterations in NSCLC

EP.07.01 Prediction of Pathologic Low-Grade Malignant Adenocarcinoma in Radiologically Invasive C-Stage IA Non-Small Cell Lung Cancer Measuring >2-3 Cm

EP.07.02 Development and Validation of a High-Speed and High-Throughput 3D Reconstruction Algorithm in Pulmonary Vasculature and Nodules Localization

EP.07.03 Lung Cancer: Artificial Intelligence, Biometrics and Modeling of Alive Supersystems for Best Management

EP.07.04 Pathological Investigation of Bronchial Stump and Bronchopleural Fistula After Anatomical Pulmonary Resection for Lung Cancer

EP.07.05 Oncologic Outcomes of Segmentectomy Versus Lobectomy in Early-Stage Lung Adenocarcinoma With High-Risk Pathologic Features

EP.07.06 Preserved Ratio Impaired Spirometry Are Associated With Poor Postoperative Outcomes in Clinical Stage I Non-Small Lung Cancer

EP.07.07 Prognostic Analysis and Molecular Characteristics of Bubble-Like Appearance-Type Lung Adenocarcinoma

EP.07.08 Quantifying Resection Margins in Lung Cancer Patients Undergoing Sublobar Resection Using CT-Based 3D Reconstruction

EP.07.09 Preliminary Results of One-Stop Shop: Results From the First Twenty-One Tumor Resections Compared to a Stage-Matched Control Group

EP.07.10 Analysis of Residual Lung Volume After Segmentectomy Using 3DCT and Risk Factors for Decline in Postoperative Pulmonary Function

EP.07.11 Comparison of Robotic Assisted Thoracoscopic Lobectomy and Video-Assisted Thoracoscopic Lobectomy for Early Stage Non-Small Cell Lung Cancer

EP.07.12 The Impact of Quantification Parameters and Clinicopathologic Characteristics on the Prognosis of Stage Ia Invasive Lung Adenocarcinoma

EP.07.13 Thoracoscopic Combined Anatomicalsublobarresection for Deep Intersegmental Small-Sized Non-Small Cell Lung Cancer

EP.07.14 Contemporary Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non Small Cell Lung Cancer

EP.07.15 Model Navigated Anchor Based Responsive CT Hybrid Surgery for Intraoperative Localization and Resection for Small Pulmonary Nodules

EP.07.16 Minor Ground-Glass Opacity Differences Were Associated With Prognostic Variation in Solid-Predominant Clinical Stage IA Lung Adenocarcinoma

EP.07.17 Patient Characteristics, Surgical Outcomes, and Treatment Decisions in Early-Stage Resected NSCLC in Canada

EP.07.18 Optimizing Intraoperative Lymph Node Dissection in Stage I NSCLC: A Risk-Stratified Approach Based on CNN Model Predictions

EP.07.19 Temporal Advances of Surgical Outcomes in Posterior Segment ectomy for Primary Lung Cancer

EP.07.20 Evolution of Overall Survival (OS) After Good Quality Curative-Intent Lung Cancer Surgery in a Population-Based Cohort

EP.07.21 The Efficacy of the ‘Lung Partial Resection Prior to Lobectomy Method’ as a No-Touch Isolation Technique in Lung Cancer Surgery

EP.07.22 Major Lung Resections for Non-Small Cell Lung Cancer: Does Postoperative Pneumonia Remain a Life-Threatening Complication?

EP.07.23 Single Port Robot and Navigational Bronchoscopy During Single Episode of Anesthesia: Less Is More

EP.07.24 Study on Complex Segmentectomy Cases at Our Institution

EP.07.25 Real-World Treatment Patterns and Outcomes of Stage I-III Resectable Non-Small Cell Lung Cancer (NSCLC) in Portugal

EP.07.26 A Novel Thoracic Localization Technique: Combining Intracorporeal Radiopaque Marker Suturing and Intraoperative Cone-Beam CT

EP.07.27 Unravelling Sublobar Resections: Real-World Outcomes after Wedge vs Segmentectomy and Recurrence Risk Factors

EP.07.28 Real-Time Image-Guided Indocyanine Green Fluorescencedual-Visualization Technique Forthoracoscopic Segmentectomy

EP.07.29 Single-Port Robotic Anatomical Lung Resection Using the Novel Chinese SP1000 Robotic System: Initial Experience

EP.07.30 Preop-Intraop Consistency in Thoracic Surgery: MRMC Reanalysis of Surgical Planning Accuracy

EP.07.31 A Comparative Analysis of Sublobar Versus Lobar Resection for Early-Stage Non-Small Cell Lung Cancer in Octogenarian Patients

EP.07.32 Initial Experience With Robot-Assisted Thoracic Surgery for Anatomical Lung Resection: A Case Series of 40 Patients From a Japanese Regional Hospital

EP.07.33 The Pictorial Fit Frail Scale as a Preoperative Risk Stratification Tool in Lung Resection Patients

EP.07.34 A Study of Lung Cancer Patients Who Survived for More Than 5 Years After Incomplete Resection

EP.07.35 Comparative Analysis of Anterior and Posterior Approaches in Robotic Pulmonary Resection

EP.07.36 Introduciton of Dural-Port Robot Assisted Thoracoscopic Lung Disection - Aiming for Reduce-Port RATS That Anyone Can Do

EP.07.37 An Initial Experience of Resectable Non Small Cell Lung Cancer From a Tertiary Care Center

EP.07.38 Immune Checkpoint Inhibitors May Not Fully Mitigate the Adverse Prognostic Impact of PD-L1 Expression in Early Lung Cancer

EP.07.39 Simply the Best: Analysis Of 1000+ Patients Comparing Single-Fraction to Three-Fraction Lung SBRT for Early-Stage Inoperable Lung Cancer

EP.07.40 Efficacy of Re-Irradiation With SABR of Lung Cancer After Primary SABR: A Single Centre Experience

EP.07.41 Individualized SBRT for Ultra-Central NSCLC Achieves Optimal Tumor Control With Minimal Toxicity

EP.07.42 Stereotactic Body Radiation Therapy Versus Surgery in Early-Stage Non-Small Cell Lung Cancer. How Does Comorbidity Impact?

EP.07.43 The Role of FDG-PET/CT SUVmax in Predicting Treatment Outcomes and Progression Risk in SBRT for ES-NSCLC

EP.07.44 Perioperative Treatment Patterns and Clinical Outcomes in Early-Stage NSCLC: A Real-World Study (Peri-R-02)

EP.07.45 Single-Cell Analysis Revealed the Characteristics of Tumors With Different Responses to Neoadjuvant Chemo Immunotherapy in Stage II-IIIB NSCLC

EP.07.46 Clinical and Radiologic Factors Associated With Surgical Eligibility After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC

EP.07.47 Real-World Implementation of Neoadjuvant Chemo-Immunotherapy in Resectable Non-Small Cell Lung Cancer

EP.07.48 The Impact of Sarcopenia on Neoadjuvant Chemoimmunotherapy in Earlier Stage Resectable NSCLC

EP.07.49 Neoadjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series

EP.07.50 Real-World Treatment Strategy and Postoperative Prognosis for Clinical Stage II/III NSCLC: A Multicenter Study

EP.07.51 Long-Term Egfr-Tki as Neoadjuvant Therapy Effectively Achieved Depth of Pathological Response

EP.07.52 PD-L1 Tumor Expression Changes in Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy and the Relation With Pathologic Response

EP.07.53 Impact of Subcutaneous Fat on the Relative Dose Intensity of Adjuvant Chemotherapy in Patients With Non-Small Cell Lung Cancer

EP.07.54 Lymphatic Permeation as a Key Risk Factor for Recurrence in Pathological Stage IIA NSCLC Under the 9Th TNM Classification

EP.07.55 Adjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series

EP.07.56 Efficacy and Safety of Postoperative Adjuvant Chemotherapy and Atezolizumab and Osimertinib Maintenance Therapy for NSCLC at Our Hospital

EP.08.01 Surgery for Resectable Lung Cancer With Radiographic Disease Control After Chemoimmunotherapy: A Retrospective Cohort Study

EP.08.02 A Study of Patients With Lung Cancer Complicated With Ipf Who Underwent Partial Pulmonary Resection

EP.08.03 Surgical Outcomes in Induction and Perioperative Chemoimmunotherapy Trials: A Meta Analysis

EP.08.04 Reducing Medication Burden and Accelerating Recovery Through Tubeless Thoracic Surgery: A Large-Scale Real-World Study

EP.08.05 Minimally Invasive Approaches for Pancoast Tumor Resection: A Comparative Analysis of Surgical Techniques and Outcomes

EP.08.06 Survival Analysis and Nomogram for Postoperative Pulmonary Sarcomatoid Carcinoma Patients: SEER Database Analysis and External Validation

EP.08.07 The Role of Surgery After Neoadjuvant Immunotherapy in NSCLC : Refining the Multimodal Paradigm

EP.08.08 Complex Tracheobronchial Reconstruction for Locally Advanced T4N2M0 Non-Small Cell Lung Cancer Using Three-Dimensional Models

EP.08.09 Aggravation of Tumor Necrosis After Transbronchial Biopsy in Lung Cancer: A Fatal Complication Despite Rescue Surgery

EP.08.10 N3 Stage May no Longer Be Considered Unresectable in Anaplastic Lymphoma Kinase(ALK)-Positive Non-Small Cell Lung Cancer: A Case Series

EP.08.11 Multimodality Approach for Locally Advanced Lung Cancer, When Is Surgery Most Beneficial in a Resource-Constrained Environments

EP.08.12 Occult Lymph Nodal Metastasis in Sub-Centimeter Lung Cancer: A Report of Seven Cases and Review of Literature

EP.08.13 Machine Learning Prediction of Overall Survival in Stage III Unresectable NSCLC: Data Analysis From a Single Center Prospective Cohort

EP.08.14 Adaptive Radiotherapy in Locally Advanced Lung Cancer - a Single-Centre Retrospective Study

EP.08.15 Predicting Locations of In-Field Failure Leading to Proton Re-Irradiation for NSCLC

EP.08.16 Impact of Pathological Subtypes and Radiation Dose on Survival in Lung Cancer: A Retrospective Analysis From a Single Institution

EP.08.17 Patterns of Recurrence and Eligibility for Salvage Therapy After Curative Intent Treatment for Unresectable Stage III NSCLC

EP.08.18 Concurrent Chemoradiotherapy (ConCRT) in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)In the Durvalumab Era

EP.08.19 Timing and Predictors of Lymphopenia in Lung Cancer Patients Undergoing Proton and Photon Chemoradiotherapy

EP.08.20 Comparative Survival Post-Radiotherapy in Small Vs. Non-Small Cell Lung Cancer: Revisiting Prognostic and Dosimetric Factors

EP.08.21 Sequential Radiotherapy Following Induction Immunochemotherapy/Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer

EP.08.22 Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

EP.08.23 EMS to Lung Cancer Patients Receiving Platinum Doublet Concomitant Chemoradiotherapy

EP.08.24 Pattern of Care in Locally Advanced NSCLC in India

EP.08.25 CRT Patterns and Short-Term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

EP.08.26 Blood Inflammatory Biomarkers Dynamics in Neoadjuvant Chemoimmunotherapy vs Chemotherapy Alone in Non-Small Cell Lung Cancer

EP.08.27 Exploration of Targeted Sequential Surgery Combined Therapy for ROS1-Rearranged Non-Small Cell Lung Cancer

EP.08.28 Referral Rates to Medical Oncology Before Lung Cancer Surgery: A Quality Improvement Study in the Era of Perioperative Chemoimmunotherapy

EP.08.29 Pathologic Response After Neoadjuvant Chemoradiotherapy Versus Chemoimmunotherapy in Resected Stage III-N2 Non-Small Cell Lung Cancer

EP.08.30 The Outcome of Preoprerative Therapy for Resectable NSCLC Patients With EGFR PACC Mutations

EP.08.31 Phase II Trial and Correlative Genomic Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-Mutant Non-Small Cell Cancer

EP.08.32 Real-World Outcome of Neoadjuvant-Intent Therapy vs Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

EP.08.33 A Real-World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy Be Recommended?

EP.08.34 To Resect or Not to Resect: The Evolving Landscape of Definitive Therapy for Stage III NSCLC: Implications for Service Demand in Ireland

EP.08.35 Accurate Pathologic Response Assessment of Lung Squamous Cell Carcinomatreated With Neoadjuvant Immunochemotherapytherapy

EP.08.36 Vebreltinib as Neoadjuvant Therapy in Three Cases of MET Exon 14 Skipping Mutation-Positive NSCLC: A Case Series

EP.08.37 Treatment Strategies for Unresectable Stage IIIA Lung Cancer After Neoadjuvant Therapy

EP.08.38 Real-World Data of Adjuvant Therapy With Aumolertinib for EGFR-Mutated NSCLC Patients

EP.08.39 Adjuvant Therapy With Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients With Exon 20 Insertion Mutations

EP.08.40 Immunotherapy Extended Survival in Patients With Recurrent Pulmonary Pleomorphic Carcinoma Following Surgery

EP.08.41 Tislelizumab Combined With Chemotherapy for Conversion Therapy in Stage III-N3 Non-Small Cell Lung Cancer: A Phase 2, Single-Arm Trial

EP.08.42 A Prognostic Marker for Consolidation Therapy With Durvalumab After Concurrent Chemoradiotherapy in NSCLC: The Utility of Serum CYFRA 21-1

EP.08.43 Surgical Stress After Lung Cancer Surgery Triggers the Outgrowth of Distant Metastases

EP.08.44 The Prognosis of NSCLC Patients Who Received Neoadjuvant Immunotherapy

EP.08.45 Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 =50%: A Systematic Review and Meta-Analysis

EP.08.46 Neoadjuvant Immunotherapy Improves Recurrence-Free Survival in Resectable Non-Small Cell Lung Cancer - a 10-Year Institutional Experience

EP.08.47 Consolidation Immunotherapy Impact in Non-Small Cell Lung Cancer: A Descriptive Analysis

EP.08.48 PD-L1 Expression and Efficacy of Durvalumab Consolidation in Stage III EGFR-Mutant Non-Small Cell Lung Cancer: A Multicenter Real-World Study

EP.08.49 Accurate Pathologic Response Assessment of Lung Adenocarcinoma Treated With Neoadjuvant Targeted Therapy

EP.08.50 Excellent Response to Osimertinib-Based Regimens in Choroidal Metastasis in Patients With EGFR Exon 19 Deleted Non-Small Cell Lung Cancer a Case Series

EP.08.51 Impact of KRAS Mutations on Outcomes in Stage III Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab

EP.08.52 Is Attrition to Surgery Even Less in a Real-World Setting After Neoadjuvant Chemo-Immunotherapy for Non-Small Cell Lung Cancer?

EP.09.01 Feasibility of High Pressure Continuous Positive Airway Pressure to Reduce Respiratory Motion in Thoracic Irradiation

EP.09.02 Consolidative Hypofractionated RT for Oligometastatic NSCLC

EP.09.03 Survival and Neurotoxicity of WBRT Vs. SRS in Individuals With Brain Metastases From Lung Cancer: Retrospective Study

EP.09.04 Duration of Systemic Therapy in Patients With Metastatic EGFR-Mutated NSCLC and Brain Metastases: First Vs. Third Generation TKIs

EP.09.05 Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-Small Cell Lung Cancer Patients:A Retrospective Study

EP.09.06 Consolidative High-Dose Thoracic Radiotherapy in NSCLC Without Progression After First-Line Systemic Therapy With ICIs

EP.09.07 Cardiac Dosimetry and Clinical Outcomes in Individuals With Lung Cancer Undergoing Thoracic Radiotherapy: Retrospective Study

EP.09.08 Outcomes of SBRT in the Management of Adrenal Metastases From Lung Cancer - Retrospective Data From Tertiary Cancer Centre of India

EP.09.09 Evaluation of Radiotherapy Use in Patients With Metastatic Solid Tumors: An Analysis of Real-World Data

EP.09.10 Salvage Surgery After Nonoperative Treatment of Initially Unresectable Stage IIIB-IV Non-Small Cell Lung Cancer

EP.09.11 Prognostic Impact of Nodal Downstaging After Neoadjuvant Therapy on Survival in Oligometastatic Non-Small Cell Lung Cancer

EP.09.12 Pleurodesis in cM0sM1a Lung Adenocarcinoma With Pleural Metastasis: Impact on Pleural Effusion Control and Survival Outcomes

EP.09.13 Prognostic Analysis of Patients With Incidentally Diagnosed Pathological Stage IVA Non-Small Cell Lung Cancer After Anatomical Resection

EP.09.14 Efficacy and Safety of Intrathecal Pemetrexed in NSCLC Patients With Leptomeningeal Metastases: A Retrospective Study

EP.09.15 CT-Guided Microwave Ablation as an Alternative Treatment for Non-Surgical Lung Cancer Patients: A Clinical Evaluation of Benefits and Risks

EP.09.16 Airway Stenting for the Treatment of Airway Stenosis in Advanced Lung Cancer; a Study of 20 Patients With Advanced Lung Cancer

EP.09.17 Permanent Local Control After Orbital Cryoablation for Ocular Metastasis From Lung Cancer

EP.10.01 Retrospective Study of Pemetrexed Monotherapy for Non-Small Cell Lung Cancer Patients by Renal Function

EP.11.01 The Challenge of Immunotherapy in Advanced Lung Cancer Patients With HIV: A Systematic Review of Case Reports

EP.11.02 Four Year-Experience With Immunotherapy in First Line Treatment of Advanced Lung Cancer in Patients With High and Very High Expression of PD-L1

EP.11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non Small Cell Lung Cancer Overall Survival

EP.11.04 Camrelizumab-Induced Immune-Related Toxic Epidermal Necrolysis in Lung Adenocarcinoma: A Case Report and Literature Review

EP.11.05 Prognostic Value of Hb/RDW and Its Correlation With Immune-Inflammatory Profile in NSCLC Receiving First-Line Immunotherapy

EP.11.06 First-Line Immunotherapy for PD-L1 =50% Advanced NSCLC vs EGFR-TKIs in EGFR-Mutant NSCLC: A Retrospective Single-Center Study

EP.11.07 Type2 Diabetes Mellitus Affect Prognosis and Immune Checkpoint Inhibitor Treatment Efficacy for Advanced Non Small Cell Lung Cancer

EP.11.08 Comparison of Efficacy and Safety of Combination Therapy With Atezolizumab and Chemotherapy in Non-Small Cell Lung Cancer

EP.11.09 Predictive Value of Markers of Systemic Inflammation in Patients With Advanced NSCLC Treated With First-Line Immune Checkpoint Inhibitors

EP.11.10 Clinicopathologic Features, Genetic Characteristics and Prognostic Analysis of Advanced Non-Small Cell Lung Cancer, Not Otherwise Specified

EP.11.11 Real World Outcomes of First-Line Pembrolizumab With or Without Chemotherapy in Patients With Non-Small Cell Lung Cancer

EP.11.12 Real-World Impact of Immune Checkpoint Inhibitors in Elderly Patients With Advanced NSCLC: A Retrospective Cohort Study From South Korea

EP.11.13 ICI Rechallenge in Non Small Cell Lung Cancer: A Retrospective Analysis of Efficacy and Prognostic Factors

EP.11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis From a Prospective Real-World Study

EP.11.15 Bimodal Onset and Pan-Cancer Uniformity of Immune-Mediated Liver Injury: A Retrospective Cohort Study

EP.11.16 Immunotherapy Rechallenge of Advanced NSCLC Patients Who Progressed on 3rd-Generation of EGFR-TKI and Immunotherapy Sequentially

EP.11.17 Promising Effect of Nivolumab With Carboplatin, Paclitaxel, and Bevacizumab in EGFR-Mutant NSCLC Following EGFR-TKI Therapy

EP.11.18 Non-Small Cell Lung Cancer Metastases to Adrenal Glands Are Not Differentially Sensitive to Immune Checkpoint Inhibitors

EP.11.19 Efficacy and Safety of Continuing Tislelizumab After Progression of First-Line Tislelizumab in Patients With Advanced NSCLC

EP.11.20 Real World-Outcomes of Advanced Non-Squamous NSCLC Patients Treated With First-Line Chemo-Immunotherapy According to KRAS Status

EP.11.21 Efficacy of Immunotherapy in EGFR-Mutant NSCLC After Tyrosine Kinase Inhibitors: Real World Analysis at a Tertiary Oncology Center in Hong Kong

EP.11.22 Efficacy and Safety of Atezolizumab Plus Bevacizumab-Based Therapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical Trials

EP.11.23 Sex-Based Differences in Immune Toxicity Without Survival Trade-Offinlate-Lineici Therapy for Lung Cancer

EP.11.24 A CT Based Tumor Microenvironment Specific Radiomics Signature for Predicting the Efficacy of Checkpoint Inhibitor Therapy in Advanced NSCLC

EP.12.01 Real-World Data of ROS-1 Positive Nsclcs- Mutational Heterogeneity, Clinical Characteristics and Its Outcomes

EP.12.02 Efficacy and Safety of Firmonertinib for EGFR Exon 21 L858R Mutation-Positive NSCLC Patients With Brain Metastases

EP.12.03 Study on the Effects of Anlotinib Combined with PD-1 Antibody in Lung Cancer Rats and Its Impact on the PLGF/Flt-1 and TGF-ß1 Pathways

EP.12.04 Efficacy of EGFR TKIs of a Rare but Sensitive Subtype of EGFR L833V/H835L Mutation in Advanced NSCLC

EP.12.05 The Effect of a Dutch Breakfast on the Exposure of Alectinib Using a Microtracer Approach: A Proof-Of-Concept Study

EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC

EP.12.07 Using Online Continuing Medical Education to Identify Ongoing Gaps in Global Clinicians’ Understanding of HER2-Altered NSCLC

EP.12.08 A Real-World Study of the Efficacy and Safety of Firmonertinib for Patients With Non-Small Cell Lung Cancer With EGFR Uncommon Mutations

EP.12.09 Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective Study

EP.12.10 Clinical Investigators’ (CIs) Preferences for First-Line Therapy of ALK-Positive Metastatic Non-Small Cell Lung Cancer

EP.12.11 Prognostic Impact of Metastatic Tumor Burden in Patients With Egfr-Mutated Lung Cancer: Real-World Data From a Single Center

EP.12.12 Efficacy of Lazertinib in Treatment-Naive Patients for EGFR Mutated Non-Small Cell Lung Cancer With Brain Metastases

EP.12.13 Gradually or Locally Progressed NSCLC Patients Benefit From Aumolertinib in Post-1L Dose-Escalation Treatment

EP.12.14 Population-Adjusted Indirect Comparisons of Repotrectinib and Taletrectinib in ROS1+ aNSCLC

EP.12.15 Predictive Value of Gastrin for the Absorption of pH-Dependent Small-Molecule Inhibitors in Patients With NSCLC

EP.12.16 Prolonged Survival in Oligometastatic ALK-Positive NSCLC: Impact of Local Ablative Therapy in a Multimodal Treatment Approach

EP.12.17 NNMT as a Therapeutic Target in EMT-Associated Osimertinib Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma

EP.12.18 Osimertinib-Associated Asymptomatic Depigmented Skin Macules in a Mexican Cohort

EP.12.19 Efficacy of Aumolertinib in Patients With Advanced NSCLC for Uncommon EGFR Exon 19 Deletion Mutations

EP.12.20 A Realworld Study: Clinical Molecular Characteristics and Prognostic Factors of NSCLC With MET Alteration

EP.12.21 The Impact of Afatinib and Osimertinib Plasma Concentrations on Treatment Toxicities, Quality of Life, and Effectiveness in Patients With NSCLC

EP.12.22 Clinical Treatment Outcomes of Erlotinib in Metastatic Non-Small Cell Cancer Harboring Uncommon EGFR Mutations

EP.12.23 Disease Burden and rwPFS as a Surrogate Endpoint for rwOS in NTRK+ NSCLC and Other Advanced/Metastatic Solid Tumors

EP.12.24 Common vs Uncommon EGFR Mutations in NSCLC and the Potential Prognostic Role of Neutrophil-To-Lymphocyte Ratio

EP.12.25 Demographic Influences on Treatment Preferences in Advanced EGFR+ mNSCLC: A Qualitative Analysis of Patient Perspectives on Osimertinib

EP.12.26 Multi-Omics Decipher the Molecular Landscape of EGFR+ Non-Small Cell Lung Cancer Patients Following Osimertinib Treatment

EP.12.27 Effect of PD-L1 Expression Level on Clinical Outcomes of Stage IV EGFR Mutant Lung Cancer Patients Treated With Osimertinib

EP.12.28 Real-World Clinical Outcomes in Chinese Patients With Advanced EGFR-Mutated NSCLC on First-Line Third-Generation EGFR-TKIs Treatment

EP.12.29 Association Between Tepotinib-Induced Edema and Clinical Outcomes in Patients With MET Exon 14 Skipping NSCLC

EP.12.30 Real-World Outcomes of Full and Reduced Dose Capmatinib and Tepotinib Treatment for MET Exon 14 Skipping Mutation NSCLC

EP.12.31 Dual Target Drug Discovery for EGFR and PIK3CA in Lung Adenocarcinoma Using Machine Learning and Molecular Simulation Techniques

EP.12.32 Targeted Therapy Utilization in Patients With Stage IV Non-Small Cell Lung Cancer Harboring Actionable Mutations

EP.12.33 Retrospective Analysis of Adenocarcinoma of Lungs From Medical Oncology Clinic in Eastern India

EP.12.34 Long-Term Control of Leptomeningeal Disease in NSCLC With EGFR Mutations: A Case Series

EP.12.35 Insights on Treatment Experience From Patients With ALK+ NSCLC Treated With 1St-Line Brigatinib, Lorlatinib and Alectinib

EP.12.36 Data Visualization of Treatment Patterns in Adults With BRAFV600EMutant mNSCLC in Real-World Settings

EP.12.37 Targeted Treatment of NSCLC With? BRAF Fusions: A Systematic Review

EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases

EP.12.39 Dynamic Evolution of Genomic and Microenvironment Landscape in ALK-Positive Non-Small Cell Lung Cancer

EP.12.40 Clinical Efficacy and Safety Analysis of Osimertinib Versus Aumolertinib in Real-World Treatment of EGFRm Advanced NSCLC

EP.12.41 FUTURE Trial:First-Stage Data of Initial Firmonertinib 160mg in EGFR+/PD-L1+ Locally Advanced or Metastatic NSCLC (Simon’s Two-Stage Design)

EP.12.42 Durable Response to ROS1-Tkis in Metastatic Squamous NSCLC With EZR-ROS1 Fusion

EP.12.43 Long Progression-Free Survival With Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series

EP.12.44 The Efficacy of Capmatinib in Treating NSCLC Patients With MET Amplification in a Multi-Center Real-World Setting

EP.12.45 Concurrent ROS1-Rearrangements of Brain Metastasis in EGFR-Mutation Lung Adenocarcinoma

EP.12.46 Efficacy of Sunvozertinib in Advanced NSCLC With HER2 Exon 20 Insertion After Prior Treatment Failure: A Real-World Case Series

EP.12.47 Persistent Response of Sunvozertinib in Lung Adenocarcinoma Patient With EGFR Exon 20 Insertion Mutation

EP.12.48 Identifying Optimal First-Line Treatment Strategy for Advanced-Stage EGFR Mutant NSCLC: A Network Meta-Analysis

EP.12.49 Osimertinib Distribution in Brain Metastases From Patients Withmetastatic Non-Small Cell Lung Cancer

EP.12.50 Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor as an Effective Subsequent Line: A Case Series From Kuwait

EP.12.51 Clinical Landscape and Future Perspectives of Targeted Protein Degradation Therapies in Lung Cancer

EP.12.52 A High-Fat Meal Optimizes the Pharmacokinetic Profile of DO-2, a Novel MET-Kinase Inhibitor for NSCLC

EP.12.53 Case Report Response to Treatment With Erdafitinib in a Patient With FGFR2 Mutation in Adenocarcinoma Lung Cancer

EP.12.54 Real-World Use of Targeted Therapy Combinations to Manage Secondary Oncogenic Addiction in Non-Small Cell Cancer

EP.12.55 Aumolertinib Combined With Metronomic Oral Vinorelbine in Advanced EGFR-Mutant NSCLC

EP.12.56 Ipd Meta-Analysis of Intracranial Efficacy: Can CNS Data Refine First-Line Choices in EGFR-Mutant NSCLC?

EP.12.57 Ensartinib Exhibits Potential Synergistic Effects With Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer

EP.12.58 Feasibility of Aumolertinib Followed by SRT in EGFR+ NSCLC Patients With Intracranial Oligo-Progression: A Phase II, Prospective Study

EP.12.59 Calcium Channel Blockers and Irreversible EGFR TKIS. Opportunities Missed?

EP.12.60 Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?

EP.12.61 Prognostic-Predictive Modeling in Advanced Non-Small Cell Lung Cancer: A Review of Biomarkers Using AI, ML and DL

EP.12.62 Identification of Optimal Candidates for the FLAURA2 Regimen in EGFR-Mutated NSCLC Based on PFS2 Analysis

EP.12.63 Combining Chemotherapy With Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experiencecombining Chemotherapy and Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experience

EP12.64 Real-World Effectiveness of First-Line Osimertinib in EGFR-Mutated NSCLC: Interim Results From the French POSITHES Study

EP.13.01 Survival Analysis of Malignant Pleural Effusion in Small Cell Lung Cancer: A Single-Center Retrospective Analysis

EP.13.02 Incidence and Characteristics of Small Cell Lung Cancer at the National Respiratory Center of Persahabatan Hospital, Indonesia in 2023-2024

EP.13.03 A Single-Center Experience With Tarlatamab in Relapsed/Refractory Advanced Small Cell Lung Cancer and Neuroendocrine Carcinomas

EP.13.04 Patients With Limited Stage Small Cell Lung Cancer Detected Through Lung Cancer Screening May Have Improved Survival

EP.13.05 Twice Daily Hyperfractionated vs Once Daily Normofractionated Chemo-Radiotherapy in LS-SCLC: A Monocentric Experience

EP.13.06 Immunotherapy for ES-SCLC Comorbid With COPD: A Real-World Retrospective Study

EP.13.07 Association of Gut Microbiota and Metabolites With Thalidomide-Induced Antiemetic Efficacy in Small Cell Lung Cancer Patients

EP.13.08 Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated With Inferior Survival

EP.13.09 Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for LS-SCLC

EP.13.10 Superior Vena Cava Syndrome in Extensive Stage (ES)-SCLC: A Marker of Aggressive Disease but Also a Window for Achieving Prolonged Survival?

EP.13.11 Real-World Survival Data Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors

EP.13.12 A Retrospective Study of the Efficacy of Chemoimmunotherapy for Extended-Stage Small Cell Lung Cancer in Elderly Patients

EP.13.13 Treatment Outcome in Limited Stage Small Cell Lung Cancer: National Retrospective Study

EP.13.14 Real-World Data Analysis of Treatment Pattern and Prognosis of Patients With Limited-Stage Small Cell Lung Cancer in Japan

EP.13.15 Outcome and Safety of Lurbinectedin as Compassionate Use in SCLC: A Retrospective Multicentric International Study

EP.13.16 Safety and Efficacy of Chemoimmunotherapy in Stage IV Small Cell Lung Cancer: A Single-Center Retrospective Analysis

EP.13.17 Efficacy of First-Line Chemoimmunotherapy With Durvalumab or Atezolizumab in SCLC - Experiences From Practice of Two Polish Oncology Centers

EP.13.18 Retrospective Evaluation of the Prognostic Impact of Anti-PD-L1 Antibodies in ECOG-PS 2-3 Patients With Extensive-Stage SCLC

EP.13.19 30-Year Review of Real-World Outcomes in Small Cell Lung Cancer at Hospital Clinic of Barcelona

EP.13.20 Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes From a Single-Institution Retrospective Study

EP.13.21 Extended Follow-Up of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: Real-World Multicenter Study

EP.13.22 Survival and Treatment Patterns in Limited Disease-SCLC: Real World Data From the Swedish National Lung Cancer Registry

EP.13.23 Tislelizumab Plus Sitravatinib or Anlotinib as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

EP.13.24 ES-SCLC Outcomes Following SBRT And/Or Thoracic Consolidation After Induction Systemic Therapy

EP.13.25 Real-World Treatment Patterns in ES-SCLC Highlight Continued Unmet Medical Need in the Era of New Therapies: ESSENCE Study

EP.13.26 Gut Microbiota and Metabolites as Potential Biomarkers for Immunotherapy Efficacy in Patients With Extensive-Stage Small Cell Lung Cancer

EP.13.27 Co-Targeting SFKs and DNA Damaging Chemotherapy Drugs as a Novel Therapeutic Strategy in SCLC

EP.13.28 Assessment of Clinical Characteristics and Outcomes of Brazilian ES-SCLC Patients on First Line Durvalumab + Chemotherapy

EP.13.29 Safety and Efficacy of DLL3 CAR-T Cells Armored With dnTGFBR2 in a Patient With Recurrent Small-Cell Lung Cancer

EP.13.30 Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice

EP.13.32 Multi-Institutional Real-World Experience of Early Tarlatamab-Related Toxicities for Extensive Stage Small Cell Lung Cancer

EP.13.33 Treatment Timeliness and Impact on Survival in Extensive Stage Small Cell Lung Cancer

EP.13.34 Meta-Analysis of First-Line Immunochemotherapy in ES-SCLC: Does ECOG PS =2 Affect Survival Outcomes

EP.13.35 Sequential Atezolizumab Regimens (Chemo Followed by Anlotinib) for ES-SCLC: Real-World Data

EP.13.36 Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer

EP.13.37 Immunotherapy Plus Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials

EP.13.38 Real-World Comparison of Carboplatin-Etoposide vs Cisplatin-Etoposide in ES-SCLC

EP.13.39 Factors Associated With Refusal of Chemoradiotherapy in Stage I-III Small Cell Lung Cancer and Their Effect on Survival

EP.13.40 Trial of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer Combined With Allopurinol and Mycophenolate (CLAMP)

EP.13.41 Expression of PD-L1 and Alternative Immune Checkpoints (ICs) and Their Impact on Outcomes in Small Cell Lung Cancer (SCLC)

EP.13.42 Self-Oxygenating PROTAC Microneedles for Spatiotemporally-Tunable Protein Degradation and Enhanced Small Cell Lung Cancer Therapy

EP.13.43 The Prognostic Factors Related With the Organ Spesific Metastasis on Survival in ES-SCLC; TROD 08-16 Study

EP.13.44 Real-World Treatment Patterns and Clinical Outcomes in Patients With Metastatic Neuroendocrine Neoplasms of the Lung (NEN-L)

EP.13.45 Efficacy and Prognostic Significance of Immunotherapy in Postoperative Recurrent and Advanced Large Cell Neuroendocrine Carcinoma

EP.13.46 Novel Prognostic Markers in Pulmonary Neuroendocrine Tumors (Carcinoid Tumors)

EP.14.01 Chemotherapy Plus Bevacizumab and Immunotherapy Prolonged the Survival of Unresectable Malignant Mesothelioma Patients in First-Line

EP.14.02 Overall Survival and PD-L1 Expression Analysis of Patients With Pulmonary Mesothelioma

EP.14.03 Glutamine Dependency of Pleural Mesothelioma

EP.14.04 Mapping the Pleural Mesothelioma: Incidence, Treatment Patterns and Outcomes From Endemic Pocket in Southern Rajasthan, India

EP.14.05 Predictive Factors of Postoperative Long-Term Survival in Patient With Pleural Mesothelioma

EP.14.06 Survival Analysis in Malignant Pleural Mesothelioma

EP.14.07 Applying Multi Criteria Decision Analysis in Health Care Decision Making in Egypt

EP.14.08 Gender Difference as a Prognostic Factor in Non-Epithelioid Pleural Mesothelioma: Survival Analysis in the Retrospective SONET Study

EP.14.09 Comparison Between Epithelioid Type and Biphasic Type in Pleurectomy/Decortication for Pleural Mesothelioma

EP.14.10 Role of CT Assessed in the Evaluation of Sarcopenia in Patient With Malignant Pleural Mesothelioma. Results From an Observational Study

EP.14.11 Comparison of Short Term Surgical Outcomes for Thymectomy With Various Minimally Invasive Approaches : A Single Center Experience

EP.14.12 Immune Profiles and Clinicopathological Insights in Thymomas: A Comprehensive Analysis

EP.14.13 Utility of Visual Assessment of PET/CT for Differentiating Malignancy in Thymic Epithelial Tumors

EP.14.14 Cyclophosphamide/Pegylated Liposomal Doxorubicin/Cisplatin as First-Line Treatment for Patients With Advanced Thymic Epithelial Tumors

EP.14.15 Patterns of Failure and Long-Term Outcomes in Patients With Thymoma Treated With Surgery and Radiation Therapy

EP.14.16 Clinical Characteristics, Surgical Risks, and Long-Term Prognosis of Good's Syndrome: A Retrospective Analysis of 108 Thymoma Cases

EP.14.17 Clinical Outcomes of Patients With Advanced Thymic Malignancies Treated With Carboplatin/Pemetrexed Vs. Pemetrexed Alone

EP.14.18 Post-Thymectomy Myasthenia Gravis: A Multicenter Retrospective Study on Clinical Characteristics and Outcomes

EP.14.19 A Single Institution Retrospective Analysis of Mediastinal Tumor Resections Utilizing Robotic-Assisted Surgery

EP.14.20 Whole-Exome Sequencing Study of Thymic Epithelial Tumors

EP.14.21 Real-World Clinical Outcomes of Patients With Masaoka Stage Iv Thymic Carcinoma Treated With Carboplatin and Paclitaxel

EP.14.22 Intrathoracic Radiotherapy in the Treatment of Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Metastases

EP.14.23 Distinct Mechanical Responses in Psp Reveal AKT1 Mutation and Mechanical Tension Synergy in EMT

EP.14.24 Report of Four Cases of Primary Pulmonary Sarcoma Experienced at Our Hospital

EP.14.25 The Initial Outcome of Single Port Robotic Surgery for Mediastinal Tumors With 16 Cases

EP.14.26 Novel Bioengineered Drugs With Immunotherapies for Malignant Pleural Effusion

EP.14.27 mTOr Inhibitor as Treatment Inpulmonary Epithelioid Hemangioendothelioma, a Case Series

EP.14.28 Three-Dimensional Reconstruction of the Sternum: A Novel Approach for Improved Surgical Outcomes

EP.14.29 A Case Study of Multiple Nodular Lesions in the Anterior Mediastinum Detected on Preoperative Imaging

EP.14.30 Clinicopathological Features and Diagnostic Challenges of Pulmonary Lymphoma: A Retrospective Review of 21 Cases

EP.14.31 Incidence Trends and Survival Outcomes of Pulmonary Langerhans Cell Histiocytosis: A National Cancer Study Using SEER

EP.15.01 Anorexia, an Underreported Adverse Event, Predicts Mortality in Lung Cancer Patients

EP.15.02 Therapeutic Efficacy of Traditional Chinese Medicine Heat Patch Therapy for People With Lung Cancer

EP.15.03 Why Are Patients With Non-Small Cell Lung Cancer in Stage I-IIIA Considered Inoperable? A Registry Study From Denmark

EP.15.04 Lung Function Before and After Development of Checkpoint Inhibitor Pneumonitis: Insights for Risk Assessment and Recovery

EP.15.05 Wearable Devices and ePROs for Perioperative Continuous Monitoring in Thoracic Surgery

EP.15.06 Bridging the Gap: Co-Designing Tools to Improve Equity in Lung Cancer Screening Care Pathways

EP.15.07 Living With Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact

EP.15.08 The Lived Experience of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery

EP.15.09 Clinical Decision Flowchart for Optimizing the Use of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Real-World Data

EP.15.10 Do Enhanced Recovery After Lung Cancer Surgery Programs Risk Putting Primacy of Caring at Stake?

EP.15.11 Patterns of Care and Outcomes in Patients With Advanced Lung Cancer in a Hospital Palliative Care Unit: A Single-Center Retrospective Study

EP.15.12 Virtual Personalized Exercise Program for Subjects With Lung Cancer: A Feasibility Study

EP.15.13 Pilot Study of Exercise Program and Monitoring by a Lung Cancer Patient Navigator During Chemoradiotherapy for Stage III Lung Cancer

EP.15.14 Empowering Lung Cancer Care: The Role of AI Chatbots to Promote Exercise Oncology

EP.15.15 Lived Experiences and Needs of People Living Long-Term With Metastatic Non-Small Cell Cancer: A Qualitative Study

EP.15.16 Patient’S Understanding of Follow-Up Post Curative Primary Lung Cancer Surgery

EP.15.17 The Role of Pneumonia in Mortality Among Hospitalized Patients With Advanced Lung Cancer

EP.15.18 Characteristics and Clinical Outcomes of Hispanic Patients With Thoracic Malignancies Requiring ICU Admission: A Single Center Experience

EP.15.19 Patients With Advanced-Stage Lung Cancer in Intensive Care Unit, a Retrospective Observational Study Assessing Their Prognosis

EP.16.01 Is Follow Up for Lung Cancer Surgery Evidence Based Within the UK - a Critical Review of Protocols

EP.16.02 Lung Cancer Patients’ Involvement and Support Preferences and Needs: Insights From a Global Patient Experience Survey

EP.16.03 Characterization of a Real-World Data Set of EGFR+ NSCLC Patients

EP.16.04 Relationship Between Telomere Length and Pulmonary Toxicity in Patients With Locally Advanced Unresectable Lung Cancer

EP.16.05 Expectations and Quality of Life of Lung Cancer Patients During the Care Process

EP.16.06 Health Literacy Leads to Health Equity; a Best Practice Approach From a Lung Cancer Organization

EP.16.07 Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter

EP.16.08 Preliminary Study of Culturally Adapted Approaches to Enhance Lung Cancer Education for Hispanic/Latino Populations

EP.17.01 Identifying Barriers to Timely Initiation of Oral Anti-Cancer Medication in Patients With Non-Small Cell Lung Cancer

EP.17.02 Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry

EP.17.03 Disparities in Lung Cancer Treatment for Older Adults

EP.17.04 Social Vulnerability as a Determinant of Disparities in Lung Cancer Management and Survival

EP.17.05 Association of Social Vulnerability With Prognosis of Lung Cancer in Japan

EP.17.06 Evolving Trends in Lung Cancer Epidemiology in India: A Shift in Patterns and Clinical Insights

EP.17.07 Using COM-B Behavioural Change Framework to Implement Lung Cancer Pathway for Primary Care Physicians

EP.17.08 Ready or Not: Assessing Provider and Facility Preparedness for Bispecific Therapy in Extensive Stage-Small Cell Lung Cancer

EP.17.09 Pulmonary Nodule Burden in Melbourne: A Snapshot Pre-Australian Lung Cancer Screening Rollout

EP.17.10 Opportunities and Challenges of Lung Cancer Diagnosis, Care and Treatment in Western Kenya

EP.17.11 Integrating Prevention and Screening of Tobacco-Related Diseases Including Lung Cancer Screening: Results of a Pilot Program

EP.17.12 Utility of CT Scans & Blood Tests After Maintenance Durvalumab Post Chemort in Stage III NSCLC Patients

EP.17.13 Healthcare Professionals’ Perceived Barriers and Facilitators of Risk-Stratified Follow-Up Care in Lung Cancer

EP.17.14 Concordance Between Clinical and Radiological Diagnoses of Pneumonitis: Retrospective Cohort Review From Regional Health Service in Australia

EP.17.15 Tackling the Lung Cancer Crisis in Canada: Co-Creating a National Strategy to Reduce Lung Cancer Mortality by 30% Action Plan?

EP.17.16 Improved Concordance to Clinical Practice Guideline: Analysis Of Multidisciplinary Team Discussed Patients With Stage III Lung Cancer

EP.17.17 Availability of PD-L1 and Ngs Results at Initial Medical Oncology Consultation in Patients With Non-Small Cell Lung Cancer

EP.17.18 Refining Lung Cancer Diagnosis Through Multidisciplinary Team Collaboration

EP.17.19 Quality Control and Analysis of Standardized Diagnosis and Treatment of Lung Cancer

EP.17.20 Natural Language Processing in Rapid Evaluation of Suspicious Lung Findings: Impact on Lung Cancer Outcomes

EP.17.21 A Digital Health Solution for Monitoring Pulmonary Symptoms in Cancer Treatment

EP.17.22 The Burden of Lung Cancer in Nigeria’s Capital City: Findings From the Population Based Cancer Registry

EP.17.23 Demographic Profile and Patient Journey of Early-Stage NSCLC Patients in a Brazilian Public Reference Center: A Real-World Study

EP.17.24 Clinicopathological Features of Lung Cancer: A Study From a Tertiaryreferral Center in Georgia

EP.17.25 The Transition of Treatment Choice for First-Line Treatment for Advanced or Recurrent NSCLC and the Patients’ Characteristics

EP.17.26 Survival in Advanced NSCLC Patients With PD-L1 =50% Treated With ICIs : A Multicenter, Retrospective Real-World Study in Georgia

EP.17.27 Real-World Impact on Overall Survival of High-Cost Targeted and Immunotherapies in Lung Cancer Patients Under Chile's DAC Program

EP.17.28 Duration of Systemic Therapy in Patients With Metastatic EGFR-Mutated NSCLC and Brain Metastases: First vs Third Generation TKIs

EP.17.29 Real-World Effectiveness of Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration

EP.17.30 Rising Incidence of Early Onset Thoracic Malignant Tumors: Real-World Data From Two Hospitals in Brazil

EP.17.31 Temporal Trends and Prognostic Factors in Lung Cancer Patients: Analysis Of a 25-Year Cohort of 2,488 Cases

EP.17.32 Real-World Disease Impact in First-Line Treated Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 Expression =50%

EP.17.33 Evolving Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer in the United States

EP.17.34 Real-World Survival Outcomes in Non-Small Cell Lung Cancer: Insights From UK Ehr-Derived Data

EP.17.35 Treatment-Associated Interstitial Lung Disease in Extensive-Stage Small Cell Lung Cancer

EP.17.36 Disparities in Survival Outcomes of Primary Pulmonary Diffuse Large B-Cell Lymphoma: A SEER Database Analysis

EP.17.37 Assessing the Hidden Risk From 1990-2021: Radon-Attributable Tbl Cancer Burden Across the European Union

EP.17.38 Intersecting Determinants of NSCLC Outcomes in Brazil: The Roles of Histology, Socioeconomic Status, and Healthcare Sector Disparities

EP.17.39 Carbon Footprint of Lung Cancer Management and Impact of Lung Cancer Screening Implementation

P3.01.01 Asian-Americans With Tobacco Use History Are Less Often Eligible for Screening Than White Individuals With Lung Cancer

P3.01.02 Association Between Age and Lung Cancer Risk: Evidence From Lung Lobar Radiomics

P3.01.03 Night Shift Work and Lung Cancer Risk: A Prospective Cohort Study With Mediator Analysis From the Uk Biobank

P3.01.04 Bootstrap-Based Mediation Mendelian Randomization Unveils Gut Microbiota-Driven Metabolic-Immune Networks in Lung Cancer

P3.01.05 Decoding the Sleep Enigma: A Proteomic Mediation Analysis Linking Healthy Sleep Patterns to Lung Cancer Risk

P3.01.06 Lung Cancer in Incidentally Detected Pulmonary Nodules: Stratified Analysis by Smoking History and Nodule Morphology

P3.01.07 Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence From an Integrated EHR Database and State Cancer Registry Data

P3.01.08 Impact of Reproductive Factors on Lung Cancer Risk in Women:A Prospective Analyses in the UK Biobank

P3.01.09 Survival Determinants and Socio-Demographic Disparities in Early Onset Lung Cancer in Young Adults: Insights From AI Modeling

P3.01.10 Income, Tumour Stage, and Treatment in Patients With Non-Small Cell Lung Cancer: A Population-Based Study in the Netherlands

P3.01.11 Lung Cancer in Young Patients Under 45 Years: Clinical Characteristics, Histology and Molecular Profile

P3.01.12 Associations Between Respiratory Diseases and Lung Cancer Risk, With New Insights Into Acute Infections

P3.01.13 Lung Cancer Characteristics and Survival Among Smokers, Former Smokers, and Never Smokers Within an Australian Lung Cancer Registry

P3.01.14 The Rising Toll: Global Burden and Future Projections of Tracheal, Bronchus, and Lung Cancer in Women, 1990-2050

P3.01.15 Quantifying the Burden of Lung Cancer Attributable to Behavioral Risk Factors in OECD Countries Over Three Decades

P3.01.16 Global Burden of Lung Cancer Attributed to High Fasting Plasma Glucose: A Benchmarking Analysis of G20 Countries (1990-2021)

P3.01.17 Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the United Kingdom From 1990-2021

P3.01.18 The Journey to a Lung Cancer Diagnosis: Reports From the LEAD Study

P3.01.19 Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review

P3.01.20 Lung Cancer Risk Factors in 35,530 People From the UKLS Trial Who Have Never Smoked

P3.01.21 Lifting the Smoke Screen: A Real-World Comparative Study of Lung Cancer in Never-Smokers Versus Ever-Smokers

P3.01.22 Deep Learning-Based CT Analysis Enhances Lung Cancer Risk Prediction in Never Smoking Women

P3.01.23 The Impact of PM2.5 Exposure on the Genome of Patients With Lung Adenocarcinoma Who Have Never Smoked

P3.01.24 Economic Burden of Radon Attributable Non-Small Cell Lung Cancer: A Cost Analysis

P3.01.25 Residential Radon and Molecular Alterations in Non-Small Cell Lung Cancer

P3.01.26 Respiratory Hazard Index Is Associated With Lung Cancer Development in Underrepresented Lung Cancer Screening Individuals

P3.01.27 Environmental Carcinogenesis in Lung Cancer: Sodium Arsenite-Induced PML Dysregulation and LINE-1 Activation

P3.01.28 Household Air Pollution and Mitochondrial DNA Fragmentation

P3.01.29 Identifying Long Term Air Pollution Exposure for Lung Cancer Risk in Canada

P3.01.30 The Relationship of Particular Matter 2.5 and Mortality Rate of Patients With Lung Cancer and Lag Time Effect in Northern Thailand

P3.01.31 Physical Characterization of PM2.5 - Effects on Cellular Uptake, Dispersion, and Lung Cell Interactions

P3.01.32 Association of Long-Term Exposure to Fine Particulate Matter, Ozone, and Greenness With Lung Cancer Risk

P3.01.33 Global Trends in Tracheal, Bronchus, Lung Cancer Burden From Household Air Pollution

P3.01.34 Associating Pollution-Related Anthracotic Pigments Within Normal Lung Tissue With Lung Cancer Characteristics

P3.01.35 Air Pollution and Lung Cancer Risk by Smoking Status: Findings From the Uk Biobank

P3.01.36 Feasibility of Implementing a Virtual Nursing-Led Smoking Cessation Clinic for Patients With Cancer

P3.01.37 Time-Dependent Analysis Reveals the Dual Role of Smoking in Non-Small Cell Lung Cancer Immunotherapy

P3.01.38 Effect of Smoking Cessation Duration on Lung Cancer Incidence: A Nationwide Retrospective Cohort Study in Korea

P3.01.39 From Nodule-Free to Nodule-Positive: Blood Biomarkers Bridge Smoking and Lung Cancer Risk

P3.01.40 10 Years Post Implementation of a Smoking Cessation (SC) Program in Regional Cancer Centres in Ontario, Canada:Successes and Ongoing Challenges

P3.01.41 Impact of Smoking Status on Survival and Radiation Toxicity in Lung Cancer Patients Receiving RT

P3.01.42 Transitions in Cigarette and E-Cigarette Use in the PATH Study: A Multistate Transition Model Analysis of Us Adults by Race and Ethnicity

P3.01.43 IMPRINT-Lung: Single-Arm, Multi-Center Phase II Trial of Immunotherapy With Pembrolizumab for Interception of High-Risk Lung Nodules

P3.01.44 Comparison of Age-Adjusted Charlson Comorbidity Index and Modified Frailty Index as a Postoperative Prognostic Indicator for Lung Cancer

P3.01.45 Restrictive Lung Function and Smoking Increase Lung Cancer Risk in Tuberculosis Survivors: A Cohort Study

P3.01.46 Characterization of Patients With Lung Cancer Not Meeting Lung Cancer Screening Criteria: Identifying a High-Risk Group Beyond Tobacco Smoking

P3.01.47 Presentation and Validation of Three Engage Variants of the PLCOm2012 Lung Cancer Risk Prediction Model

P3.01.48 Familial Lung Cancer and Hereditary Patterns in NSCLC - Implications for Risk Redefinition

P3.01.49 A Pro-Mitotic Gene Expression Module in Small Airways Links COPD Severity to Non-Small Cell Lung Cancer

P3.01.50 Association Between Chronic Lung Diseases and Lung Cancer: A Bidirectional Two-Sample Mendelian Randomization Study

P3.01.51 Evidence Synthesis of Non-Screen-Eligible Cohorts and Implications for Lung Cancer Advocacy

P3.01.52 Unseen Risks: Rethinking Lung Cancer Screening for Hispanic Communities

P3.01.53 Germline EGFR Mutations Are Enriched in the Southeast United States and Associated With High Penetrance of Non-Small Cell Lung Cancer

P2.02.01 Characterizing UPP1 Expression in Non-Tumor Cells of Lung Cancer and Its Clinical Implications

P2.02.02 R-Loop-Associated DNA Damage Facilitates Chemosensitivity of NSCLC

P2.02.03 Ferroptosis-Induced SUMO2 Lactylation Counteracts Ferroptosis by Enhancing ACSL4 Degradation in Lung Adenocarcinoma

P2.02.04 Patient-Derived Large Cell Neuroendocrine Carcinomas Actively Interact With Glutamatergic Neurons and Impair Their Function

P2.02.05 CXCL12/CXCR4 Axis Mediates M2 Monocyte Polarization-Induced Immune Resistance in NSCLC Liver Metastasis

P2.02.06 Functional Impact of Missense Mutations Affecting Immune Response Genes in Human Cancer

P2.02.07 Targeting SLC4A7 Reprograms the Acidic Tumor Microenvironment to Overcome Immunotherapy Resistance in NSCLC

P2.02.08 A Unique VEGFA-Expressing CAF Subpopulation Emerges in TKI-Resistant Lung Cancer to Mediate Immunotherapy Sensitization and Adverse Outcomes

P2.02.09 Early-Stage Lung Adenocarcinoma: PLVAP-Driven Regulation of the Tumor Microenvironment

P2.02.10 Emotional Distress Following Lung Cancer Surgery and Tandospirones Dual Benefits for Chemotherapy

P2.02.11 SRC Activation Drives Acquired Pemetrexed Resistance in Non-Small Cell Lung Cancer and Is Targetable by Dasatinib

P2.02.12 hUC-MSC-Derived Exosomes Mitigates Immune Checkpoint Inhibitor-Associated Lung Injury by Suppressing GSDME-Mediated Pyroptosis

P2.02.13 Macrophages Exhibit Enhanced Cholesterol Efflux in Early-Stage Lung Adenocarcinoma

P2.02.14 Urolithin a Alleviates Radiation Pneumonitis by Activating PINK1-PRKN-Mediated Mitophagy

P2.02.15 Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma

P2.02.16 Identification of Deruxtecan-Induced Methylome Signature in NSCLC Cell Lines

P2.02.17 GNAZ as a Tumor Suppressor Marker Inhibits Tumor Development Through Interaction With the KIF11 Protein

P2.02.18 Crosstalk Between Oncogenic Signaling Pathways and Immune Checkpoint Proteins in Pleural Mesothelioma

P2.02.19 SIN3A/MIR22HG/Beclin1 Axis Regulates Both Autophagy and Ferroptosis in Lung Adenocarcinoma

P2.02.20 Targeting BTN1A1 in Pd=D-L1-Negative NSCLC: A Clinically Actionable Immune Checkpoint for Docetaxel-Based Combination Therapy

P2.02.21 CTNNB1 Activates LINC01426 to Promote Metabolic Reprogramming in Lung Adenocarcinoma Cells by Regulating NFAT5 Nuclear Translocation

P2.02.22 Analysis of FGF19 in Lung Squamous Cell Cancer Tissue and Cell Models

P2.02.23 Screening of Autophagy Related Genes in Lung Squamous Cell Carcinoma and Study of Their Mechanisms of Action

P2.02.24 Zongertinib Has Activity Against NRG1 Fusion Positive Tumor Cells

P2.02.25 Elevated SGO2 Expression in Lung Adenocarcinoma Promotes Migration and Invasion by Regulating MAD2, Correlating With Poor Prognosis

P2.02.26 Establishment of a HER2 Overexpressing Lung Squamous Cell Carcinoma Cell Line Sensitive to Targeted and Cytotoxic Therapies

P2.02.27 Osimertinib Increases Expression of HER2 and Combination With T-DXd, a HER2-Directed ADC, Enhances Its Efficacy in PDX Models of EGFR Mutant NSCLC

P2.02.28 Proteasome Inhibitor Causes Proteotoxic Death and Reshapes TME in LKB1-Deficient NSCLC by Blocking Er-Stress Repair Addiction

P2.02.29 CXCR2 Inhibitor Plus KRAS G12C Inhibitor Remodels Immunosuppressive Tumor Microenvironment in KRAS G12C-Mutant NSCLC?

P2.02.30 Targeting MTA2 Lactylation as a Therapeutic Strategy to Overcome Chemoresistance in Lung Adenocarcinoma

P2.02.31 The Changes of Macrophage in EGFR Mutant TKI-Resistant Patients With Lung Cancer

P2.02.32 Homeostatic Dysregulation of Systemic CD8+ T Cell Compartment in Lung Cancer Patients

P2.02.33 Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer

P2.02.34 Synergistic Antitumor Effect of an XPO1 Inhibitor And/Or Sotorasib With V-ATPase Inhibitors Pretreatment in KRAS G12C NSCLC

P2.02.35 Association of Intratumoral Microbiota Composition With Tertiary Lymphatic Structure of Lung Adenocarcinoma

P2.02.36 Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers

P2.02.37 ERBB3-BCAR4 Is a Recurrent and Oncogenic Fusion in Lung Adenocarcinoma Cases That Lack Other Driver Alterations

P2.02.38 Single-Cell RNA-Sq Reveals Potential Mechanism of RUNx3 Reshaping TME in NSCLC

P2.02.39 Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect With Omeprazole Pretreatment in KRAS G12C NSCLC

P2.02.40 Multiomics Assessment of Lung Adenocarcinoma Subtypes Defined Through Tumor Purity-Adjusted DNA Methylation

P2.02.41 Feasibility of Flow Super RCA for KRAS Mutation Detection in Liquid Biopsies of Advanced Lung Adenocarcinoma: Pilot Study

P2.02.42 Effect of MTHFR Gene Mutation on the Efficacy of Tyrosine Kinase Inhibitor Treatment in Lung Cancer Patients

P2.02.43 Multi-Omic Approach Elucidates the Underlying Mechanism of HA-Coated Neohesperidin Nanoparticles Against Lung Cancer

P2.02.44 Research on the Mechanism of Gut Microbiota Promoting NSCLC Distant Metastasis Through Its Metabolite Testosterone

P2.02.45 Modulated Electro-Hyperthermia Enhances Tumor Cell Susceptibility to Gamma Delta T Cell-Mediated Cytotoxicity and Tumor Infiltration

P2.02.46 V-Atpase Inhibitors Enhance the Effect of Tepotinib (c-Met Inhibitor) or RMC-6236 (Pan-Ras(ON) Inhibitor) in KRAS-Mutant NSCLC

P3.03.01 Rb Inactivation as a Hallmark of Squamous Transformation in EGFR-Mutant Lung Cancers

P3.03.02 WEE1 as the Target for Circumvention of ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutated Lung Cancer

P3.03.03 Mechanisms of Osimertinib Tolerance in Mutant EGFR Lung Cancer PDX Models

P3.03.04 Aggressive Lymph Node Dissection Is Linked to Poor Survival and Impaired Anti-Tumor Immunity in Non-Small Cell Lung Cancer

P3.03.05 Proteomic Analysis of Pleural Mesothelioma

P3.03.06 Integrated Bulk and Single-Cell Transcriptomics Reveals Immune Ecotype Heterogeneity in EGFR-Mutated Lung Adenocarcinoma

P3.03.07 Characterization of Live Cell Repository for Tumor Derived Pleural Mesothelioma Cells and Cancer Associated Fibroblasts

P3.03.08 Patient-Derived Tumour Organoids Recapitulate Keratinizing Lung Squamous Cell Carcinomas

P3.03.09 Synonymous Mutations in PDGFRA Exons 12 and 18 Correlate With Reduced Survival and Serum Iron Levels in Non-Small Cell Lung Cancer

P3.03.10 Establishment of Patient-Derived Organoids From EBUS-TBNA Cytological Samples in Lung Cancer Patients

P3.03.11 Anlotinib Exerts a Protective Effect on Radiation Lung Injury Through the Regulation of the Immune Microenvironment Mediated by M2c Macrophages

P3.03.12 YAP-Driven Modulation of HER3-Mediated Adaptive Resistance to RET Inhibitors in RET-Altered Cancer

P3.03.13 HLA II Genetics Shapes Lung Cancer Immunosurveillance

P3.03.14 PCSK9-Mediated Immune Escape as a Mechanism of Acquired Resistance to PD-1/PD-L1 Blockade

P3.03.15 Investigating Mechanisms of Resistance in EGFR-Mutated Non-Small Cell Lung Cancer Through High Resolution Transcriptomics

P3.03.16 CXCR2+ Neutrophils Influence Immunotherapy Efficacy in NSCLC Patients With KL Subtype

P3.03.17 Intermittent Caloric Restriction Synergies With KRAS(OFF) Inhibitors in Preclinical Models of KRASG12C Lung Adenocarcinoma

P3.03.18 Single-Cell Transcriptomic Analyses of Lung Immune Cells Reveal That Mitf-Driven Plcb1HighMacrophages Induce Radiation-Induced Lung Injury

P3.03.19 SFRP2highCAFs Trigger CD8+T Cell Apoptosis to Sustain Abscopal Resistance to Radioimmunotherapy in Lkb1-Mutant Lung Tumors

P3.03.20 Citrullinated Vimentin Is an Effective Target for CAR T Cells in Non-Small Cell Lung Cancer

P3.03.21 Aptamer-Drug Conjugates for Leptomeningeal Carcinomatosis and Cancer-Associated Cachexia in Lung Cancer

P3.03.22 Tumor Treating Fields (TTFields) Downregulate DNA Repair and Show Efficacy in Small Cell Lung Carcinoma Preclinical Models

P3.03.23 Circular Rna Vaccine Synergizes With Anti-PD-1 to Augment Therapeutic Efficacy in Lung Cancer

P3.03.24 Oxydock: Optimizing Lung Cancer-Targeted Therapy Through Oxygen-Responsive Molecular Docking

P3.03.25 A Combination Therapy Strategy That Targets Both KRAS-G12C and GSK3 for Non-Small Cell Lung Cancer

P3.03.26 Ir-Metal Framework Loaded With Radiation-Responsive Anti-Angiogenic Prodrugs for Enhanced Radiotherapy Efficacy

P3.03.27 The TXNRD1-IGF2BP3 Axis Promotes EGFR-TKI Resistance and Identifies a Therapeutic Vulnerability in NSCLC

P3.03.28 Tumor Treating Fields (TTFields) Concomitantly With Anti-PD-1 and Cisplatin in a Mouse Model of Non-Small Cell Lung Cancer

P3.03.29 IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

P3.03.30 Activation of EGFR Signaling Mediated by PTPRR Methylation Causes Resistance to KRAS Inhibitor Sotorasib

P3.03.31 Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients With Lung Adenocarcinoma

P3.03.32 Multi-Omic Characterization of ALK Fusion LUADs Reveals Overactivation of DNA Replication as a Contributor to ALK TKI Resistance

P3.03.33 Clinical and Genomic Landscape of BRAF-Mutant NSCLC Patients From the AACR GENIE BPC Cohort

P3.03.34 Assessment of Minimal Residual Disease Using Liquid Biopsy in Patients With EGFR-Mutated Lung Cancer Treated With Osimertinib

P3.03.35 Association of Intestinal Flora and Metabolites With Bone Metastasis in Patients With Non-Small Cell Lung Cancer

P3.03.36 Whole Genome Doubling Drives Genomic Instability and Poor Postoperative Outcomes in Stage I Driver-Negative Lung Adenocarcinoma

P3.03.37 Target Lipid Metabolism in Immune Microenvironment: Immunotherapy Sensitization and Combinatorial Strategies for NSCLC With Liver Metastases

P3.03.38 Oncolytic Virus Effectively Delivers CD47 Blockade to Suppress Tumour Growth in Preclinical NSCLC Models

P3.03.39 Deep Learning Based Multiplex Imaging Platform for High Throughput ADC Targets Expression Quantification and Biomarker Discovery in NSCLC

P3.03.40 PRMT9 mRNA Stabilized by IGF2BP1 in an m6A-Dependent Manner Promotes Proliferation and Metastasis of Lung Adenocarcinoma Cells

P3.03.41 FOXO3A Regulates NSCLC Radiotherapy Resistance Through PINK1/Parkin Pathway of Protective Mitophagy

P3.03.42 Immune-Related Gene Expression Profiling and ALK-TKI Efficacy for Patients With ALK-Rearranged Non-Small Cell Cancer

P3.03.43 Gut Klebsiella Pneumoniae Drives Lung Cancer Progression by Modulating Macrophage Hpgds and Suppressing the PGJ2-PPAR? Signaling Pathway

P3.03.44 High Frequency of SMARCA4 Inactivating Mutations in Advanced NSCLC and Their Association With Low PD-L1 Expression

P3.03.45 KRAS Mutations Shape an Oxidative, Immune-Cold Tumor Microenvironment Driving Chemo-Immunotherapy Resistance in Advanced NSCLC

P3.03.46 Phenotyping Double Negative B Cells in Non-Small Cell Lung Cancer

P3.03.47 Study of Genomic Intra-Tumor Heterogeneity and Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

P3.03.48 Fluorescence Lifetime Imaging in Fixed NSCLC Samples Demonstrate Differences Between Tissue Compartments

P3.03.49 Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Cells Harbouring RET Fusions

P3.03.50 cIRCCAMSAP1 Induce Osimertinib Resistance in Lung Adenocarcinoma by Downregulating the Degradation Level of HSPA1A

P3.03.51 FLT3LG Improve Therapeutic Sensitivity to Anti-PD-1 Therapy by Modulating Immune Cell Infiltration in NSCLC

P3.03.52 XPO1 Inhibition Reduces Tumor Growth Potential by Inhibiting Wnt Signaling Pathway in Lung Squamous Cell Carcinoma

P3.03.53 WISP3 Drives NSCLC Progression by Upregulating SDCBP via the TGF-? Signaling Pathway

P3.03.54 Influenza'S Silent Warriors: Unveiling Lung Tumor Cell Assassination Through Macrophage Reprogramming via SAA4-MLKL Axis

P1.04.01 Stage Shift and Then Some - St. Elizabeth Healthcare's Notable Journey, 50,000 Screens Later

P1.04.02 Performance of AI Vs. Radiologists in the 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Annual Follow-Up Results

P1.04.03 Comorbidities and Social Factors in Lung Cancer Screening Eligibility: Insights From the Colaus and Lc65 Cohorts in Switzerland

P1.04.04 Effect of Social Determinants of Health on Lung Cancer Screening Uptake in the U.S

P1.04.05 Diminishing Eligibility for Lung Cancer Screening According to Standardized Screening Guidelines

P1.04.06 AI Performance for Lung Nodule Growth in UK Lung Cancer Screening: Expert Consensus and Histological Validation

P1.04.07 Projection of the Lung Cancer Screening Eligible Population in Argentina From 2000 to 2050

P1.04.08 Program Guidelines for Australia’S National Lung Cancer Screening Program: A Robust and Consultative Development Approach

P1.04.09 Size Distribution and Short-Term Progression of New Nodules From the 4ITLR Lung Cancer Screening Trial

P1.04.10 Lung Cancer Screening Completion Rates as Predicted by Social Deprivation

P1.04.11 New Nodule Lung Cancer in the UK Lung Cancer Screening Trial: Characteristics and Comparison With NELSON

P1.04.12 Smoking Duration Lung Screening Criteria (Potter Criteria) Captures More Underrepresented Individuals at Risk for Lung Cancer

P1.04.13 The Impact of Reconstruction Kernel and Hounsfield Unit Threshold on Emphysema Quantification From Lung Cancer Screening Data

P1.04.14 Age, Risk Thresholds and Cost-Effectiveness: Evaluating Lung Cancer Screening Using the PLCOm2012 Model

P1.04.15 Lung Cancer Screening in Switzerland: Baseline Results From the Vaud Pilot Project

P1.04.16 Real-World Outcomes of Lung Cancer Screening and High-Risk Lung-RADS 4 Nodules at VA Northern California Health Care System

P1.04.17 Poor Utilization of Lung Cancer Screening Among Cancer Survivors in the United States

P1.04.18 Diagnosis of Sub-Cm Lung Nodules With Deep Learning Segmentation and Radiomics-Based Machine Learning Classifiers

P1.04.19 Evaluating the Impact of Electronic Reminders on Lung Cancer Screening

P1.04.20 Barriers to Lung Cancer Screening Among Overdue Patients; a Quality Improvement Initiative

P1.04.21 Molecular Profiles of Clinical and Radiological Features in Pre-Invasive Lung Adenocarcinoma

P1.04.22 The Relationship Between Nodular Pleural Tail Sign and Metastasis or Recurrence of Peripheral Lung Cancer

P1.04.23 Real-World Predictive Performance of Lung-RADS in the Evaluation of Part-Solid Nodules

P1.04.24 TabPFN Empowered the Ternary Classification of Histological Subtypes in Stage IA LUADs Based on AI Analyzed Histogram Features

P1.04.25 Incidental Findings From the Annual Follow-Up in the 4-In-The-Lung-Run Lung Cancer Screening Trial

P1.04.26 The Impact of Brain MRI Surveillance on Survival Outcomes in Initially CNS Metastasis-Free Non-Small Cell Lung Cancer

P1.04.27 Radiologic Features Identification of Pathologic Tumor Invasion in Pure Ground-Glass Nodules

P1.04.28 Correlation Between Dosimetric Parameters and Radiation-Induced Pulmonary Toxicity in Lung Cancer Radiotherapy

P1.04.29 Female Asians Who Never Smoked With Lung Adenocarcinomas (FANSA) Have Unique Survival Outcomes: An ILCCO Analysis

P1.04.30 Screening of Paraptosis-Related Prognostic Genes in Lung Adenocarcinoma By Bioinformatics Analysis and Experimental Validation

P1.04.31 Implementation of a Lung Cancer Risk Prediction Algorithm: Early Findings From the Lungflag™ Pilot at Geisinger Health System

P1.04.32 Moving Forward in Early Detection: The ACS/NLCRT Best Practice Guide for Building Lung Cancer Early Detection Programs

P1.04.33 Sybil Pilot for Incidental Pulmonary Nodules

P1.04.34 AI Powered Incidental Pulmonary Nodule Program Demonstrates High Lung Cancer Detection Rate: Canadian IDEAL Study

P1.04.35 Impact of lung cancer screening eligibility criteria on participants’ characteristics and healthcare resources

P1.04.36 LungFlagTM Risk Prediction Validation on Canadian Ever Smokers Pre-Classified as High Risk for Lung Cancer

P1.04.37 Systematic Enrolment for Lung Cancer Screening Ensures Rapid Stage Shift of Diagnosed Lung Cancers at a Population Level

P1.04.38 The Coincidental Findings of Lung Nodules With AI-Assisted Chest X-Rays in the Tuberculosis Screening Project

P1.04.39 Markov Model Approach to Optimize Lung Cancer Screening and Early Detection in Patients With Smoking Associated Diseases

P1.04.40 Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: The AQC Ensemble Model

P1.04.41 Survival Differences Following Surveillance Detected Vs. Symptom Detected Recurrence in Patients With Lung Cancer

P1.04.42 Circulating Tumor Cells Combined With Solid Nodular Ratio to Predict High-Risk Pathological Subtypes of Stage Ia Lung Adenocarcinoma

P1.04.43 Evaluating the Role of Digital Tomosynthesis in Lung Cancer Screening: A Cost-Effective Alternative to Annual LDCT in Resource-Limited Settings

P1.04.44 Clinical Efficiency of Repeat CT-Guided Transthoracic Needle Biopsy of Peripheral Lung Lesions

P1.04.45 Multi-Center Validation of a Circulating 9-microRNA Signature for Lung Cancer Early Detection

P1.04.46 Predicting Malignancy in Ground-Glass Opacity Using Multivariate Regression and Deep Learning Models: A Proof-Of-Concept

P1.04.47 Breathomics Meets Deep Learning: A Novel Approach for Early Detection of Lung Cancer

P1.04.48 Rapid Intra-Operative Detection of Visceral Pleural Invasion in Non-Small Cell Lung Cancer Using Label-Free Multiphoton Microscopy

P1.04.49 Targeting VEGFR3 Nir Fluorescent Probe for Identification of NSCLC Metastatic Lymph Nodes an Exploratory Study on Surgical Navigation

P1.04.50 Fluorescein-Free Confocal Laser Endomicroscopy for Intraoperative Diagnosis of Pulmonary Nodules: A Comparative Study With Frozen Section

P1.04.51 Exploring the Potential of Multimodal Cough Analysis as a Pre-Screening Tool for Non-Small Cell Lung Cancer Detection

P1.04.52 A Clinically Applicable and Generalizable Deep Learning Model for Segmenting Anterior Mediastinal Tumors Across Multiple Institutions

P1.04.53 Potential for AI as First Reader in Lung Cancer Screening

P2.05.01 The Role of Robotic-Assisted Bronchoscopy and Endobronchial Ultrasound in Diagnosing and Staging Pulmonary Carcinoid

P2.05.02 Evolution and Survival Impact of Endobronchial Ultrasound (EBUS) Adequacy in Two Population-Based Lung Cancer Cohorts

P2.05.03 Minimizing Atelectasis in ENB: A Propensity-Matched Study of Laryngeal Mask Ventilation Strategy

P2.05.04 Electromagnetic Navigation-Guided 3D Conformal Microwave Ablation for High-Risk Peripheral Pulmonary Nodules

P2.05.05 Prediction of Distant Metastasis Using CT/PET-Based Radiomics in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

P2.05.06 Mature Results of a High-Precision Clinical Protocol for Staging Non-Small Cell Lung Cancer (NSCLC) of the Left Lung

P2.05.07 The Effect of Adrenal Gland Metastasis on the Course of Lung Cancer

P2.05.08 Discordance Between Clinical and Pathological Invasive Size in Early Stage Non-Small Cell Lung Cancer

P2.05.09 Proposed Modification of Clinical T Categorization for Early-Stage Lung Adenocarcinoma:A Data-Driven Multicenter Quantitative Analysis

P2.05.10 Prognostic Factors in IIB-IIIB Patients With Nodal Involvement Underwent Surgery for NSCLC

P2.05.11 Prognostic Impact of Organ-Specific Metastasis in Non-Small Cell Lung Cancer

P2.05.12 Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma

P2.05.13 M1a With Pleural or Pericardial Effusion Have Worse Survival Than Those With Pleural or Contralateral Lung Metastasis When Receiving EGFR-TKIs

P2.05.14 Clinical Versus Pathological T Staging in Lung Adenocarcinoma: Discrepancies and Prognostic Implications

P2.05.15 Management-Oriented Classification of Lung Neuroendocrine Tumors Based on a French Surgical Cohort of 1,915 Patients From the EPITHOR Database

P2.05.16 Comparative Discriminative Performance of Number-Based and 9th Edition N Classifications in NSCLC: Exploring Statistically Valid Cut-offs

P2.05.17 European Single-Center Validation of the 9Th TNM Staging System in Over 3,300 Surgically Treated NSCLC Patients

P2.06.01 Prognostic Value of a Combined Model Using CT and PET/CT Parameters for Predicting STAS in Stage I Lung Adenocarcinoma

P2.06.02 Invading Through External Elastic Lamina Is Predictive of Poorer Outcomes in Pulmonary Non-Mucinous Invasive Adenocarcinoma

P2.06.03 Diagnostic Performance of Frozen Section in Determining Histological Patterns and Spread Through Air Spaces in Lung Adenocarcinoma

P2.06.04 Artificial Intelligence-Led Characterisation of Lethal Morphologies in Lung Adenocarcinoma

P2.06.05 Diagnosis of the Novel IASLC Grading System Using Intraoperative Frozen Section: A Prospective Multi-Center Trial

P2.06.06 Bronchiolar Adenoma With Malignant Transformation? New Insights Based on Morphologic, Immunophenotypic, and Genomic Analysis of 13 Cases

P2.06.08 ERBB2 Mutations in Non-Small Cell Lung Cancer - Findings From a Large UK Cohort

P2.06.09 Clinical, Racial, and Genetic Differences in Non-Small Cell Lung Cancer Between Young and Older Patients in the AACR Project Genie Database

P2.06.10 Title: Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-Small Cell Lung Cancer: A cBioPortal Analysis

P2.06.11 Factors Impacting Receiving EGFR Test Results Before Initial Treatment Among Stage Iv Non-Small Cell Lung Cancer Patients

P2.06.12 TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes

P2.06.13 Actionable Mutation Profiles and Survival Outcomes in Invasive Mucinous Adenocarcinoma of the Lung

P2.06.14 Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-Small Cell Lung Cancer in a Tertiary Institution in Singapore

P2.06.15 Genomic Alterations in Lung Cancers Associated With Fibrosing Interstitial Lung Diseases in a French Multicentric Cohort

P2.06.16 Identification of Molecular Signatures Linked to Early-Stage Lung Adenocarcinoma With STAS Using Spatial Transcriptomics

P2.06.17 Cellular Heterogeneity and Tertiary Lymphoid Structure Dynamics Predict Overall Survival in Immune Checkpoint Therapy-Treated NSCLC Patients

P2.06.18 Computational Modeling of Comprehensive Genomic Profiling to Predict Chemotherapy Benefit in Advanced NSCLC

P2.06.19 A Multi-Source Pathology-Based Model for Gene Mutation and Recurrence Risk Prediction in Lung Cancer

P2.06.20 Assessment of Molecular Testing in Stage IV Non-Small Cell Lung Cancer Patients Across American Oncology Network

P2.06.21 Differential Gene Expression and Pathway Analysis of Invasive Mucinous Adenocarcinoma

P2.06.22 Pathological Characterization of Molecularly Screened Diffuse Pleural Mesothelioma

P2.06.23 CDKN2A Deletion Is an Independent Predictive Biomarker for Immunotherapy Response in Patients With Advanced NSCLC

P2.06.24 Primary Pulmonary Neuroendocrine Immunophenotype Carcinoma Harboring Driver Gene Mutation/Fusions: Neuroendocrine Neoplasm?

P2.06.25 Clinical Implications of TROP2 Expression in Lung Adenocarcinomas

P2.06.26 The Clinicopathological Characteristics and Prognostic Analysis of SMARCA4-Deficient Non-Small Cell Lung Cancer

P2.06.27 Unlocking the Genetic Link: Exploring Germline EGFR T790M Mutations in NSCLC and Implications for Targeted Treatment and Familial Screening

P2.06.28 GPC3 Upregulation After Neoadjuvant Chemoimmunotherapy Associates With Adverse Outcomes and Tumor Heterogeneity in Squamous NSCLC

P2.06.29 Bridging Histopathology and Molecular Profiling: AI-Powered Virtual Multiplex Immunofluorescence Staining for LUAD Prognosis

P2.06.30 ITGBL1: A Predictive Biomarker for IPF-LUSC Comorbidity Risk in Lung Transplant Candidates

P2.06.31 Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical Impact and Prognostic Insights From Histopathology

P2.06.32 Impact of piR_004530 Reactivation in Lung Cancer: Implications for Recurrence and Survival of Lung Squamous Cell Carcinoma Patients

P2.06.33 Prognostic Significance and Therapeutic Potential of LILRB4 in Mdsc-Mediated Immunosuppression in NSCLC

P2.06.34 Tumor Heterogeneity Based Prognostic Score: What the Specimen Tells Us in the Intelligent Era?

P2.06.35 Extracellular Vesicle RNA Diversity in Lung Adenocarcinoma: Driving Immunosuppression and Metastasis

P2.06.36 Proteomic Atlas Reveals Organ-Specific Metabolic and Functional Shifts in Preclinical Icb-Related Pneumonitis and Colitis

P2.06.37 NGS Testing in Lung Cancer Within the Catalan Precision Oncology Program: The ICO-HUB Comprehensive Cancer Center Experience

P2.06.38 BTN1A1 and Nuclear YAP1 Co-Expression as Predictive Biomarkers for Nelmastobart Efficacy in Lung Cancer: Findings From a Phase 1 Trial

P2.06.39 Predicting Relapse and TKI Response Using DNA and RNA EGFR VAF in EGFR-Mutant Lung Adenocarcinoma

P2.06.40 Integrated Molecular Analysis of Advanced NSCLC Depicts Molecular Signatures Associated With Tyrosine Kinase Inhibitors Efficacy

P2.06.41 Real-World Data and Utility of Newly Proposed Grading System From IASLC for Invasive Lung Adenocarcinoma in Japan

P2.06.42 NSD3 Overexpression Predicts Prognosis and Immune Cell Infiltration Patterns in Lung Squamous Cell Carcinoma: A Bioinformatics Analysis

P2.06.43 Estimating Tumour Microenvironment Cellular States From Bulk RNAseq Produces Biomarkers of Clinical Outcome Across Stages

P2.06.44 More Than a Mutation: Prevalence of HER2 Overexpression, Amplification, and Mutations by Histology in NSCLC

P2.06.45 A Novel Predictive Gene Signature for Liver Metastasis (LM) in NSCLC Using a Comprehensive Linked Clinical-Molecular Database

P2.06.46 Multi-Omics Analysis Reveals Genomic Features Associated With Combination Immunotherapy Benefit in Advanced NSCLC

P2.06.47 Axl Receptor Shedding and EMT in Lung Adenocarcinoma: Prognostic Implications Based on STAS

P2.06.48 Histology-Specific Genomic and Immune Predictors of Resistance to Neoadjuvant Chemoimmunotherapy in Early-Stage Non-Small Cell Lung Cancer

P2.06.49 Spatial Metabolomic Profiling Reveals Dynamic Metabolic Reprogramming During Lung Squamous Cell Carcinoma Evolution

P2.06.50 Transcriptomic Profiling Identifies a Prognostic and Predictive Immune Signature in Patients (Pts) With Lung Squamous Cell Carcinoma (LUSC)

P2.06.51 Tumour Tissue Extracellular Vesicle (EV) Biomarkers of Lung Cancer in Patients With or Without Heavy Smoking Histories

P2.06.52 Survival and Mutational Differences of GPER and Estrogen Receptor (ER) in NSCLC

P2.06.53 TP53 Mutations Drive Therapeutic Resistance in ALK-Rearranged Lung Adenocarcinoma

P2.06.54 miR-Roring IFN-Gamma Pathway Activity as a Predictive Tool for Immunotherapy Response in Non-Small Cell Lung Cancer

P2.06.55 Association Between Pathologic Necrosis and Postoperative Recurrence in Stage IA Non-Small Cell Lung Cancer

P2.06.56 Enhancing Lung Cancer Diagnosis and Early Recurrence Risk Detection via Bedside Atomic Force Microscopy

P2.06.57 TIM-1+ B Cells Promote Immune Suppression and Predict Poor Prognosis in Lung Adenocarcinoma

P2.06.58 Predictive Value of Tumor Microenvironment Biomarkers in Neoadjuvant Immunotherapy Combined With Chemotherapy for Locally Advanced NSCLC

P2.06.59 Multi-Level Screening of MET Aberrations in Treatment-Resistant Non-Small Cell Lung Cancer: A Report From LC-SCRUM-TRY

P2.06.60 Multimodal Diagnostic Model for Intraoperative Diagnosis and Surgery Strategy in Stage Ia LUAD (SuRImage V2): A Prospective, Multicentric Study

P2.06.61 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer

P2.06.62 Integrin-ß6 Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma

P2.06.63 The Role of the Lower Airway Microbiome in Predicting Treatment Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer

P2.06.64 Fusion Transcript Burden Is Associated With Clinical Outcomes in Patients With Resected NSCLC

P2.06.65 An Ensemble Approach to Predict Three-Class PD-L1 Expression From H&E Whole-Slide Images

P2.06.66 Novel Predictive Spatial Biomarker in NSCLC: Discriminant of Niches Unlocking Treatment Sensitivity (DONUTS)

P2.06.67 Retrospective Analysis of 124 LCNEC Tumors With Targeted Expression Profiling of 111 Samples Identifies Candidate Chemo-Sensitivity Biomarker

P2.06.68 Enhancing Precision Medicine in NSCLC - the Importance of Tumor Metabolic Spatial Profiling in Immunotherapy Biomarker Discovery

P2.06.69 Metabolite Enrichment Patterns Correlate With Race, Gender and BMI in Lung Cancer Patients

P2.06.70 Concurrent Tissue and ctDNA-Based Genomic Profiling in Advanced Lung Cancer: A Prospective, Single-Institution Study

P2.06.71 Clonal Hematopoiesis and Its Association With Lung Cancer Incidence and Immunotherapy Response: A Meta-Analysis

P2.06.72 Impact of Peripheral Electrolyte on Equilibrium Between Immunotherapy Toxicity and Survival in Advanced NSCLC Treated With PD-L1 Blockade

P2.06.73 Cerebrospinal Fluid Biomarkers in Patients With Leptomeningeal Metastasis of Lung Cancer

P2.06.74 Detection of Actionable Biomarkers in Liquid Biopsy From Non-Small Cell Lung Cancer Patients Using NGS-Based Assays

P2.06.75 Liquid Biopsy NGS Accelerating Treatment Decision-Making in Non-Small Cell Lung Cancer

P2.06.76 Molecular Profiling of Lung Cancer Brain Metastases: Analysis Between Liquid Biopsy and Brain Metastasis Tissue Results

P2.06.77 A Perioperative Circulating Tumor DNA Model for Landmark Detection in Non Small Cell Lung Cancer

P2.06.78 Using a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer Patients

P2.06.79 Deciphering Genomic and Transcriptomic Heterogeneity in Circulating Tumor Cells at Diagnosis in Small Cell Lung Cancer: CTC-CPC Study

P2.06.80 Development of a Proteomics-Based Machine Learning Model for Diagnosing and Predicting Lung Cancer: Insights From the UK Biobank

P2.06.81 Circulating Tumour Cells, Spread Through Air Space and Lymph-Nodal Micrometastasis in Surgically Resected Early-Stage NSCLC

P2.06.82 Cell Free DNA Dynamics in Exhaled Breath Condensate to Predict Outcomes to Immune Checkpoint Inhibition in Advanced NSCLC

P2.06.83 Multimethod Circulating Tumor DNA Profiling for Minimal Residual Disease Monitoring in Early-Stage Non-Small Cell Lung Cancer

P2.06.84 Tracking Ctc Phenotypes in SCLC Liquid Biopsies as a Diagnostic and Therapy Response Assessment Tool

P2.06.85 Clinical Utility of a “Plasma 1st Approach” for Molecular Diagnosis Using ctDNA in Advanced Lung Cancer, NHS England Pilot

P2.06.86 Development and Validation of Peripheral Blood 5-Protein Signature Predicting the Efficacy of Immunotherapy in Advanced NSCLC

P2.06.87 Reversible Smoking-Dependent Hpg80 Increase, a Path to Identifying NSCLC-Negative Individuals: An Incentive to Quit Smoking?

P2.06.88 CfDNA and WBC DNA Sequencing Through MSK-ACCESS Powered With SOPHiA DDM to Delineate Tumor and Clonal Hematopoiesis TP53 Variants in Lung Cancer

P2.06.89 DYNAMALK: DYNAMic ct-DNA in ALK+ NSCLC Under the Australasian Thoracic Cancers Longitudinal Cohort Biobank Study (AURORA)

P2.06.90 The Role of ctDNA Tumor Fraction in Advanced NSCLC and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study

P2.06.91 Plasma Proteomic Profiling Identifies DHX9 as a Predictive Biomarker for Chemoimmunotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer

P2.06.92 Host-Derived Biomarkers of Inflammation and Body Composition Predict Immunotherapy Outcomes in Advanced NSCLC

P2.06.93 Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis

P2.06.94 "Integrating AI-Based Risk Stratification, LDCT, and Liquid Biopsy for Early Detection of Lung Cancer in High-Risk Individuals"

P2.06.95 Deep Learning-Based Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer: Automated Tumor and Muscle Evaluation

P2.06.96 Exploration the Heterogeneity of HER2 Expression in Potential Candidates for Antibody-Drug Conjugate in Non-Small Cell Lung Cancer

P2.06.97 Monitoring the Risk of Second Primaries Through Blood miRNA Testing: Follow-Up of the BioMILD Lung Cancer Screening Trial

P2.06.98 Deep Learning-Based 18F-FDG PET/CT Radiomics Model for Predicting Pathological Response to Chemoimmunotherapy in NSCLC

P2.06.99 Tumor-Associated Neutrophil Infiltration Predicts Benefit From Combination Chemoimmunotherapy in Non-Small Cell Lung Cancer

P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC

P2.06.101 Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit From Sequential Thoracic Radiotherapy and ICI in ES-SCLC

P2.06.102 Prevalence and Concordance Analysis of MET Amplification/Overexpression in a Phase 1 Study of Davutamig (REGN5093) in a NSCLC

P1.07.01 Wearable-Based Evaluation of Tubeless Thoracic Surgery for Early-Stage Lung Cancer

P1.07.02 Septum-Guided Segmentectomy vs Lobectomy for Deeply Located cT1abN0M0 Non-Small Cell Lung Cancer

P1.07.03 Effectiveness of a Generalizable AI Based Automated Workflow Recognition Model in Multiple Approaches to Lung Resection

P1.07.04 MRD Combined With Radiological Tumor Volume as Tool to Identify Resected NSCLC Patients at High Risk of Recurrence

P1.07.05 Real-World Biomarker Testing and Treatment Initiation in Patients With Resected Early-Stage NSCLC (eNSCLC) in the US and UK

P1.07.06 Impact of Mediastinal Lymph Node Dissection/Sampling on Survival in Frozen Section-Upgraded Invasive Lung Adenocarcinoma

P1.07.07 The Presence of STAS Leads to Poor Prognosis After Sublobar Resection in Stage I NSCLC: Results From an Individual Patient Data Metanalysis

P1.07.08 Comparing Outcomes of Different Surgical Methods for Small-Sized NSCLC With VPI- A Population-Based Study

P1.07.09 Real-World Efficacy of an AI-Driven 3D Reconstruction System on Pulmonary Surgery

P1.07.10 Prognostic Impact of Resection Margin Distance in Patients With Completely Resected Stage INSCLC After Lobectomy

P1.07.11 AI-Based 3D Reconstruction in Lung Surgery

P1.07.12 Independent Risk Factors for Occult Lymph Node Metastasis in cIA Left Upper Lobe Lung Adenocarcinoma: A Nomogram-Based Prediction Model

P1.07.13 Impact of TP53 Co-Mutation in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma

P1.07.14 Exploring the Effect of Surgical Resection on Quality of Life in Older Adults for Stage IA Non-Small Cell Lung Cancer

P1.07.15 Oncologic Outcomes of Sublobar Versus Lobar Resection for Clinical Stage IA Pure Solid Non-Small Cell Lung Cancer

P1.07.16 The Association Between Sarcopenia and Postoperative Outcomes and Survival in Lung Cancer Patients Who Underwent Curative Resections

P1.07.17 A Neglected Dimension in Lung Cancer Surgery: Sleep Disorders Before and After Anatomical Resection

P1.07.18 Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study

P1.07.19 Prospective Cohort Study on Stage 1A Non-Small Cell Lung Cancer in Older Adults (>80 Years): Prevalence, Surgical Treatment, and Complications

P1.07.20 Feasibility of Limited Resection in Invasive Mucinous Adenocarcinoma of the Lung

P1.07.21 Lobectomy Versus Multi-Segmentectomy for Left Upper Lobe Lung Cancer: A Propensity Score-Matched Analysis

P1.07.22 LANTERN1: AI Model for Postoperative Complications Prediction for NSCLC Lung Resection: Prospective Multicentric Study and Extern Validation

P1.07.23 Impact of Pulmonary Resection on Early Postoperative Cardiac Function

P1.07.24 Radicality of Lymphadenectomy in NSCLC Resection: Impact on Survival. Results From the Spanish Video-Assisted Thoracic Surgery Group (GEVATS)

P1.07.25 Trajectories of Synchronous Subsolid Nodules in Patients With Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study

P1.07.26 Applicability of Artificial Intelligence Based Tumor Segmentation in Planning for Sublobar Resection in Lung Cancer: A Meta-Analysis

P1.07.27 A Newly Developed 3D Simulation System for the Preoperative Planning for Central-Located Lung Cancer

P1.07.28 Segmentectomy vs Lobectomy for Clinical Stage IA1-2 NSCLC and Upstaging Due to Pathologic Visceral Pleura Infiltration

P1.07.29 Prediction of Postoperative Pulmonary Function and Blood Flow Redistribution Using SPECT/CT in Patients Undergoing Lobectomy

P1.07.30 Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-Mucinous Lung Adenocarcinoma After Surgery

P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer

P1.07.32 Prognostic Value of Consolidation-To-Tumor Ratio in Stage IA Solid Predominant Non-Mucinous Adenocarcinoma

P1.07.33 Sublobar Resection Versus Lobectomy in Peripheral NSCLC After Neoadjuvant Chemoimmunotherapy: A Retrospective Study

P1.07.34 Toxicity Profile for Connective Tissue Disease Patients Treated With Lung Stereotactic Body Radiation Therapy

P1.07.35 Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

P1.07.36 A Three-Gene Signature Predicting Local Recurrence in Stage I-III NSCLC Patients Treated With Radiation Therapy

P1.07.37 Using Tissue and Blood to Find Oncogenic Drivers Upfront in Patients With Lung Cancer Evaluated for Neoadjuvant Therapy-LEADER

P1.07.38 Neoadjuvant Iruplinalkib in Resectable ALK/ROS1 Fusion-Positive NSCLC: Updated Results of the Exploratory Neo-INFINITY Study

P1.07.39 Pooled Efficacy and Safety Profile of Neoadjuvant Therapies in Operable EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis

P1.07.40 Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

P1.07.41 Exhaled Breath Analysis in Patients With Resectable NSCLC Treated With Neoadjuvant Immune Checkpoint Inhibitors

P1.07.42 Multi-Temporal Imaging and CT-To PET Translation Based Predictive Model on Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer Patients

P1.07.43 Clinico-Genomic Correlates of Pathologic Response to Neoadjuvant Chemo-Immunotherapy in Patients With Early-Stage NSCLC

P1.07.44 Multicenter Assessment of Clinical-Radiomic Predictors for Pathologic Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy

P1.07.45 Transforming Outcomes With Neoadjuvant Chemo-Immunotherapy in Operable Non-Small Cell Lung Cancer (NSCLC): A Propensity-Matched Analysis

P1.07.46 Adjuvant Systemic Therapy for Resected Stage IB-IIA NSCLC (AJCC 8Th Edition): A Real-World Cohort Study From SEER Database

P1.07.47 Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

P1.07.48 Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC With High-Risk Pathological Factors

P1.07.49 Limited Impact of Adjuvant Chemotherapy in Alk-Positive Stage II-III Adenocarcinoma: A Multicenter CReGYT-03 ALK Study

P1.07.50 Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC With High-Grade Histological Patterns: 3-Year Dfs Rate Updated

P1.07.51 Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data From the Italian ATLAS Registry

P1.07.52 Clinicopathologic Risk Score to Guide Adjuvant Chemotherapy in Stage IB NSCLC: Toward Integration of AI-Assessed Tumor Immune Signatures

P1.07.53 Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC : Also Effective in Patients With Multiple Prognostic Risk Factors

P1.07.54 The Effect of Adjuvant EGFR-TKI Therapy on the Prognosis of Pathological Stage I Invasive Lung Adenocarcinoma With Sensitive EGFR Mutation

P1.07.55 Molecular Profiling of Neo-Adjuvant IO Disclosures Residual Cancer Cells in pCR NSCLC: A Single Cell Analysis of CTONG 1804

P1.07.56 Combining Lymph Nodes and Tumor Radiomics Enhances Immunotherapy Efficacy Prediction in Non-Small Cell Lung Cancer

P1.07.57 Alterations in the Gut Microbiota and Metabolites in Patients With Liver Injury Induced by Third-Generation EGFR-Targeted Drugs

P2.08 .01 Double Lung Transplantation in Patients With Recent History of Malignancy

P2.08 .02 Long Term Prognosis Following Wedge Resection in Peripheral = cT1b Non-Small Cell Lung Cancer Patients Without Pulmonary Dysfunction

P2.08 .03 Differentgrades of Visceral Pleura Invasion in Lung Adenocarcinomas Correlate With Aggressiveness and Poor Prognosis

P2.08 .04 Open Versus Thoracoscopic Versus Robotic Sleeve Lobectomy for Central Non-Small Cell Lung Cancer: A Network Meta-Analysis

P2.08 .05 Robotic-Assisted Versus Video-Assisted Sleeve Lobectomy for Central Non-Small Cell Lung Cancer: A Multicenter Cohort Study

P2.08 .06 Clinical Significance of Tertiary Lymphoid Structures in Surgically Resected Stage II-III Lung Adenocarcinoma

P2.08 .07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy

P2.08 .08 Treatment Options and Prognosis for Lung Cancer in Elderly Patients(?80 Years Old)

P2.08 .09 Surgical Resection After Induction Therapy in Initially Unresectable Driver Mutation-Negative Stage III Non-Small Cell Lung Cancer (NSCLC)

P2.08 .10 Perioperative Outcomes of Extended Sleeve Resection at Our Institution

P2.08 .11 Management of High-Grade Endobronchial Pre-Invasive Lesion: To Treat or Not to Treat?

P2.08 .12 Salvage Stereotactic Ablative Radiotherapy for Loco-Regional Recurrence After Initial Surgery According to the START NEW ERA Phase II Trial

P2.08 .13 Radiation Dose to the Heart and Cardiac Substructures Associated With Adverse Cardiac Events in Locally-Advanced Non-Small Cell Lung Cancer

P2.08 .14 Tumor Volume Changes During Stereotactic Body Radiotherapy for Lung Tumors Under Mri Guidance

P2.08 .15 Cardiac Prioritized Planning in Locally Advanced Non-Small Cell Lung Cancer: Comparison of Modern RT Techniques

P2.08 .16 National Real-World Data on the Treatment of Locally Advanced NSCLC With Chemoradiotherapy and Adjuvant Durvalumab

P2.08 .17 Differential Cardiac Dose Evaluation and the Need of Planning Risk Volume (PRV) Margin for the Heart

P2.08 .18 Evaluation of Target Volume Delineation Variability in NSCLC Radiotherapy

P2.08 .19 Proton Beam Therapy for Lung Cancer in Patients With Interstitial Lung Disease: Initial Experience From the United Kingdom

P2.08 .20 VMAT vs IMRT Technique in Locally Advanced Lung Cancer Radiotherapy Treatment -Pulmonary Toxicity and Dosimetric Evaluation

P2.08 .21 Mapping Early Failure After CRT and Durvalumab in NSCLC: Insights From a Real-World Cohort

P2.08 .22 In Field Progression Rates Following Concurrent Chemoradiotherapy for Stage III Non Small Cell Lung Cancer

P2.08 .23 Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy With Durvalumab in PD-L1 High LA-NSCLC

P2.08 .24 Radiation Dose to the Circulating Blood Is Associated With Poor Overall Survival in Patients With Locally Advanced Non-Small Cell Lung Cancer

P2.08 .25 A Novel CT-Derived Biomarker of Immune Reserve Predicts Survival in Lung Cancer

P2.08 .26 Randomized Phase II Trial of Adjuvant Radiochemotherapy, Concurrent Versus Sequential, in Resected pN2 NSCLC. ARCCS Trial

P2.08 .27 Impact of CD73 on Immune Evasive Contexture and Clinical Outcomes in Lung Adenocarcinoma in Neoadjuvant Immunotherapy

P2.08 .28 Impact of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Stage III NSCLC: Real-World Analysis From Spanish ReSECT Database

P2.08 .29 Phase 2 Trial of Neoadjuvant Tislelizumab Combined With Chemotherapy for Newly Diagnosed Stage III Unresectable NSCLC

P2.08 .30 Ia-Based Prediction in NSCLC Patients Undergoing Neoadjuvant Radiochemotherapy

P2.08 .31 Clinical and Imaging Characteristics Associated With Pathologic Response After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC

P2.08 .32 Single Cell Transcriptomic Analysis Reveals Tumor Immune Remodeling and Epithelial Cells Gene Signature After Neoadjuvant Immunotherapy

P2.08 .33 Quantitative Pathological Analysis of the Surgical Specimens of NSCLC After Neoadjuvant Immunochemotherapy

P2.08 .34 Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Single-Arm Study

P2.08 .35 PD-L1 as a Predictive Biomarker in EGFR-Mutated Non-Small Cell Lung Cancer With Neoadjuvant Immunochemotherapy

P2.08 .36 Survival Outcomes in Locally Advanced NSCLC Patients Converted to Resectable Disease by Neoadjuvant Therapy

P2.08 .37 Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Real-World Evidence From a Spanish Multicenter Cohort

P2.08 .38 Identifying Risk Factors for Recurrence in Non-Small Cell Lung Cancer Patients With Pcr After Neoadjuvant Immunochemotherapy

P2.08 .39 Targeting CHCHD3-cGAS to Remodel Immunosuppressive Microenvironment in Lung Adenocarcinoma: Mechanism and Clinical Translation

P2.08 .41 The Influence of Perioperative Chemoimmunotherapy on Surgery for Resectable Non-Small Cell Lung Cancer:A Systematic Review and Meta-Analysis

P2.08 .42 Impact of Delayed Initiation of Adjuvant Chemotherapy on Overall Survival Among Patients With Non-Small Cell Lung Cancer

P2.08 .43 Perioperative Adebrelimab Plus Chemotherapy in Patients With Resectable Stage II-III NSCLC: 4-Year Update From a Phase 1b/3 Trial

P2.08 .44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study

P2.08 .45 Immune Gene Guided Multi-Scale Pathomic Signature in H&E-Wsi Predict Neoadjuvant Immunotherapy Response in NSCLC

P2.08 .46 COPD Reshape the Tumor Microenvironments of NSCLC and Potentiate Antitumor Efficacy of Anti-PD-1 Therapy

P2.08 .47 Lymphocyte Recovery and Risk for Immune Pneumonitis After Chemoradiation in Locally Advanced NSCLC

P2.08 .48 Pacific Real-World Experience at Hospital Doce De Octubre

P2.08 .49 Effect of the Immunological Circadian Rhythm on Treatment of Locally Advanced Non-Small Cell Cancer With Immunotherapy

P2.08 .50 Tislelizumab With Chemotherapy as Neoadjuvant Therapy for Unresectable Stage III Lung Cancer: A Single-Arm, Phase II Trial

P2.08 .51 Outcomes From a Phase II Study of Hypofractionated Chemoradiation and Consolidation Immunotherapy in Locally-Advanced NSCLC

P2.08 .52 Optimizing Lung Cancer Radiation Therapy: Integrating Immunotherapy and Targeted Therapy for Enhanced Clinical Outcomes

P2.08 .53 Safety Results of DEDALUS Trial: Sequential CT-IO, Hypofractionated RT and Consolidation IO in Unresectable Stage III NSCLC

P2.08 .54 Contemporary Treatment Patterns and Outcomes in Stage III NSCLC in the Immunotherapy Era

P2.08 .55 Comprehensive Analysis of Baseline Genomic Features and Plasma ctDNA Dynamics in Unresectable Locally Advanced NSCLC

P2.08 .56 Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience

P2.08 .57 Small Volume Segmental Lung Autotransplantation for Treatment of Central Lung Cancer:One Case Report

P2.08 .58 Advancing Care in NSCLC: Evaluating the Impact of New Treatment Modalities on Patient Outcome at the LTZ of the Comprehensive Cancer Center Zurich

P2.08 .59 SCGB1A1 Enhances Radioimmunotherapy Efficacy and Mitigates Pulmonary Toxicity via Dendritic Cell Functional Reprogramming

P2.08 .60 Telomere Length and Survival in Patients With Locally Advanced Unresectable Lung Cancer: Is There a Relationship?

P3.09.01 Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC With Brain Metastases From India

P3.09.02 Stereotactic Mr-Guided Adaptive Radiotherapy (SMART) for Ultracentral Non-Small Cell Lung Cancer (NSCLC)

P3.09.03 Efficacy of Radiotherapy in Patients With Oligo-Progressive Non-Small Cell Cancer - a Retrospective Analysis

P3.09.04 Macrophage CD38 Expression as a Predictive Biomarker for the Abscopal Effect in Lung Cancer Undergoing Radiotherapy-Immune Therapy

P3.09.05 Prognostic Value of TNM 9Th Lymph Node Classification and Pathological Node Count in NSCLC Patients

P3.09.06 Primary Tumor Resection Confers Survival Benefit in cM0sM1a Lung Adenocarcinoma

P3.09.07 Local MDT Improve the Survival of Leptomeningeal Metastasis in NSCLC With EGFR Mutation From the CLM-Tree Registry

P3.09.08 Tumor Treating Fields for Patients With Metastatic Non-Small Cell Lung Cancer: Real World First Experience

P3.09.09 Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer

P3.09.10 Safety and Efficacy of Co-Ablation System Therapy in Patients With Lung Cancer: A Single Arm Cohort Study

P2.10.01 Maintenance Pemetrexed/Pembrolizumab vs Maintenance Pembrolizumab Alone in Advanced Non-Squamous Non-Small Cell Lung Cancer

P2.10.02 Developments in Treatment of Non-Small Cell Lung Cancer and Their Implications for National Practice.Registurk-Lung National Registry Study

P2.10.03 Long-Term Pemetrexed Administration Poses Risk of Renal Function Decline

P2.10.04 Real-World Evidence on the Efficacy of TS1 in Patients With Advanced Non-Small Cell Lung Cancer

P2.10.05 Real-World Efficacy of Second-Line Carboplatin Plus Pemetrexed in EGFR-Mutant NSCLC. an International, Multicentre Analysis

P2.10.06 Docetaxel in NSCLC: A Multi-Centre Real World Evidence Analysis in the Immunotherapy Era

P2.10.07 Combined Immunoscore for Predictive Stratification of Unresectable Non-Small Cell Lung Cancer

P2.10.08 Antibody-Drug Conjugates Versus Docetaxel for Previously Treated Advanced NSCLC: Systematic Review and Meta-Analysis of RCTs

P2.10.09 Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-Small Cell Lung Cancer

P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload

P2.10.11 Single-Cell RNA Sequencing Identifies ALCAM and Gpnmb as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung

P2.10.12 Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant NSCLC: Final Results From the DESTINY-Lung05 Study

P2.10.13 Sunvozertinib Combined With Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations

P2.10.14 Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) a Phase II Randomized Study

P2.10.15 Mechanistic Study of Osimertinib Combined With Sitravatinibto Overcome Acquired Osimertinib Resistance in Non-Small Cell Lung Cancer

P2.10.16 Paclitaxel Liposome Combined With Immunotherapy in the First-Line Treatment of Advanced NSCLC: Updated Results of a Real-World Study

P2.10.17 Dual PARG-TOP1 Inhibition Exacerbates Dna-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing Top1i-ADC Efficacy

P1.11.01 First-Line Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metastatic NSCLC: Real World Data in Italy

P1.11.02 Impact of Prophylactic Use of Cardioprotective L-Carnitine on First-Line Chemoimmunotherapy in Advanced NSCLC: A Cohort Study

P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis

P1.11.04 Prediction of Overall Survival in Lung Cancer Patients With Different Organ Metastases: A SEER Population-Based Cohort Study

P1.11.05 Efficacy and Multi-Omics Insights of Immune Checkpoint Inhibitors in NSCLC With Leptomeningeal Metastasis

P1.11.06 Risk Factors and Prognosis of Immune Checkpoint Inhibitor-Induced Pneumonia in Lung Cancer With Interstitial Lung Disease

P1.11.07 Impact of Radiotherapy and Immune Checkpoint Inhibitor Combination in Advanced NSCLC: Real-World Data (RWD) Analysis

P1.11.08 Peripheral Inflammatory Biomarkers Predict Immunotherapy Retreatment Outcomes in Advanced NSCLC

P1.11.09 SBRT Combined With Tislelizumab and Granulocyte-Macrophage Colony-Stimulating Factor in Advanced NSCLC Progressing on Immunotherapy

P1.11.10 Serum Neopterin and Mortality in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

P1.11.11 Survival Impact of Pneumonitis in Older Patients With Non-Squamous NSCLC Treated With Pembrolizumab and Pemetrexed: Insights From CJLSG1901

P1.11.12 Impact of Body Composition on Immunotherapy Response in Non-Small Cell Lung Cancer

P1.11.13 A Phase II Study of Camrelizumab Plus Docetaxol in Advanced NCSLC Pre-Treated With Immune Checkpoint Inhibitors and Chemotherapy

P1.11.14 Depth of Response to Immunotherapy Is Associated With Survival Outcomes in Oligoprogressive NSCLC: A Real-World Data Analysis

P1.11.15 PD-(L)1 Inhibitors for Treatment of Locally Advanced or Metastatic NSCLC in Asian and Non-Asian Patients: A Meta-Analysis

P1.11.16 Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-Small Cell Lung Cancer

P1.11.17 PD-(L)1 Inhibitors Rechallenge in Patients With Advanced NSCLC Previously Treated With Immunotherapy: A Systematic Review and Meta-Analysis

P1.11.18 Real-World Characterization of Response Kinetics in Patients With Metastatic NSCLC Receiving First-Line Immunotherapy

P1.11.19 Real-World Outcomes of Nivolumab Plus Ipilimumab in Elderly NSCLC Patients (=75): A Retrospective Analysis

P1.11.20 Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials

P1.11.21 Target Lesion Necrosis Percentage as a Predictor for Response to Immune Checkpoint Inhibitors in NSCLC: A Retrospective Analysis

P1.11.22 Extracellular Vesicle-Derived LncRNA Signatures in Serum for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis

P1.11.23 Co-Culturing LCOs and Lymphocytes Derived From Pleural Effusion Potentially Implement Personalized Immunotherapy

P1.11.24 Real-World Evidence of Primary Resistance to First-Line Chemo-Immunotherapy in Advanced Lung Adenocarcinoma

P1.11.25 Genomic Characterticers, Survival and Prognostic Analysis of Advanced NSCLC With Kirsten Rat Sarcoma Mutations With Brain Metastases

P1.11.26 Temporal Optimization of Radiotherapy-Immunotherapy Synergy for NSCLC Brain Oligo-Metastases: Prospective Assessment of Prognosis Outcomes

P1.11.27 Optimal Immunotherapy Regimen for STK11 or KEAP1 Mutant Metastatic Non-Small Cell Lung Cancer

P1.11.28 Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study

P1.11.29 ICIs Plus Paclitaxel-Based Chemotherapy Is an Optional Treatment for Transformed SCLC After EGFR-TKI

P1.11.30 The Efficacy of Immunotherapyfor Patients With Advanced Lung Cancer and Oncogenic Driver Alterations

P1.11.31 Dynamic Monitoring of Circulating Tumor Cells and Single-Cell Sequencing Predict Therapeutic Efficacy in Advanced Lung Cancer

P1.11.32 Quality of Life Outcomes from the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK- Mutated NSCLC

P1.11.33 The Role of Rhamnose Derived From Gut Microbiome in Modulating the Efficacy of Non-Small Cell Lung Cancer Immunotherapy

P1.11.34 First-Line Camrelizumab Plus Chemotherapy in 3004 Patients With Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study

P1.11.35 RATIONALE-303: Long-Term Outcomes With Tislelizumab in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

P1.11.36 Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry

P1.11.37 Impact of Immunotherapy on Overall Survival in Advanced Non-Small Cell Lung Cancer: A Real-World Evidence Analysis

P1.11.38 Measuring the Effect of Age and Ethnicity on Outcomes in Patients With Advanced Lung Cancer Treated With Immunotherapy: A New Zealand Analysis

P1.11.39 The BLIP Score: A Tool for Non-Small Cell Lung Cancer Patients With Brain Metastases

P1.11.40 The Hidden Impact of Creatinine Clearance Estimation Method on Pemetrexed-Based Chemoimmunotherapy in NSCLC With Low PD-L1 Expression

P1.11.41 Intrapleural Dual Blockade of IL-6 and PD-L1 Reprograms CAF Dynamics and the Tumor Microenvironment in Malignant Pleural Effusion

P1.11.42 Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-Analysis

P1.11.43 Analysis of Characteristics and Predictive Factors for Long-Term Benefit of Immunotherapy in Advanced NSCLC

P1.11.44 Efficacy and Safety of Immunotherapy as First-Line Treatment in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma

P1.11.45 Real-World Prognosis of Non-Squamous NSCLC Patients With Liver, Bone, or Brain Metastases Treated With Frontline Therapies

P1.11.46 RATIONALE-303: Post-Hoc Analysis of Tislelizumab Monotherapy in Previously Treated Non-Small Cell Lung Cancer With Metastases

P1.11.47 Clinical Outcomes of Immune Checkpoint Inhibitors Treatment for Postoperative Recurrence in Non-Small Cell Lung Cancer

P1.11.48 Scoreit - Is IC3 Similarly Predictive as TC3 for Single Agent PD-1/PD-L1 Immune Checkpoint Inhibition in Metastatic NSCLC (mNSCLC)

P1.11.49 The Impact of the Lung Microbiome on Checkpoint Inhibitor Pneumonitis: Early Findings From the Australian TRACKER Lung Cancer Biobank

P1.11.50 Survival Outcomes in Advanced Pulmonary Sarcomatoid Carcinoma Treated With Immunotherapy: An NCDB Analysis

P1.11.51 Effects of Immune Checkpoint Inhibitors on the Pulmonary Circulation in Lung Cancer Patients

P1.11.52 Impact of Disease Progression on Pros in Patients Receiving Cemiplimab/Chemotherapy Versus Chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2

P1.11.53 Organ-Specific Survival in Metastatic NSCLC Patients Treated With Chemo-Immunotherapy: A Machine Learning-Based Retrospective Analysis

P1.11.54 Lack of Durable Response to ICI Therapy in Advanced NSCLC: The Role of Circulating Lazy T Cells

P1.11.55 Identifying Patients Cured From Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy

P1.11.56 Distinct Predictive Effects of PD-L1 Tps on Immunotherapy Outcomes and Immunophenotype in Squamous Versus Non-Squamous NSCLC

P1.11.57 Association Between CD274 (PD-L1) Gene Expression and PD-L1 Immunohistochemistry in Non-Small Cell Lung Cancer Specimens

P1.11.58 Efficacy of First-Line Treatment in Driver-Negative Non-Small Cell Lung Cancer With Liver Metastases : A Bayesian Network Meta-Analysis

P1.11.59 Effect of IFNG Expression Levels on Real-World Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Receiving Immunotherapy

P1.11.60 Interstitial Lung Abnormalities and MUC5B Polymorphism in Immune Checkpoint Inhibitor Pneumonitis

P1.11.61 Effects of Probiotic Duration and Type on Immunotherapy Efficacy in Non-Small Cell Lung Cancer With or Without Antibiotics

P1.11.62 Deep Learning Histopathology Model for PD-L1 (TPS) and Immunotherapy Outcome Prediction in Non-Small Cell Lung Cancer

P1.11.63 Shifts of Mutational Signatures Reveal Response Variability to Pembrolizumab-Based Immunotherapy in NSCLC Patients

P1.11.64 Vision Foundation Model to Predict Immunotherapy Treatment Response in Lung Cancer Patients

P1.11.65 Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor PD-L1 Expression Level

P1.11.66 Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights From the APOLLO11 Study

P1.11.67 VEGFR1/PD-L1 CAR-T cell treatment of solid tumor-derived malignant pleural effusion/ascites

P1.11.68 Multi-Omic Profiling Identifies Key Factors Associated With Response to Ivonescimab (AK112) in Non-Small Cell Cancer

P1.11.69 Efficacy of Immunotherapy ± Chemotherapy in Metastatic NSCLC with KRAS, STK11, or KEAP1 Mutations: A Network Meta-Analysis

P1.11.70 Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy

P1.11.71 RMT in Non Small Cell Lung Cancer

P1.11.72 Phase II Study of Combination Azacitidine and Entinostat and Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

P1.11.73 Tiragolumab Plus Atezolizumab and Bevacizumab in Immunotherapy-Refractory, Pd-L1+, Advanced Non-Squamous Non-Small Cell Lung Cancer

P1.11.74 Phase Ib Study of Golidocitinib Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC: Dose-Escalation Safety Using BOIN Design

P1.11.75 A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC

P1.11.76 Bevacizumab Plus Serplulimab and Chemotherapy for EGFR-TKI-Resistant Non-Squamous Non-Small Cell Cancer: A Phase2Study

P1.11.77 A Comprehensive Analysis of Front-Line Regimens for Stage IV Non-Squamous Non-Small Cell Lung Cancer: A 13-Year Experience

P1.11.78 NAI, An IL-15 Superagonist, A New Class Of Lymphocyte Stimulating Agent (LSA) Prolongs OS In NSCLC By Reversing Lymphopenia

P1.11.79 A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs

P1.11.80 Tumor-Derived Complement Factor B Drives Tumor Growth and Anti-PD-1 Resistance in STK11-Mutant Lung Adenocarcinoma

P1.11.81 Low-Dose Nivolumab With Platinum Doublet Chemotherapy in Patients With Advanced Central Squamous Cell Lung Cancer (SCAR)

P1.11.82 Study of THIO Sequenced With Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-Resistant aNSCLC: Improvement in PFS

P1.11.83 Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology

P1.11.84 Phase II Trial of Tislelizumab Combined With Anlotinib and 2-Cycle Chemotherapy as First-Line Treatment for Advanced NSCLC

P3.12.01 Phase II Trial of First-Line Double-Dose Firmonertinib in Locally Advanced or Metastatic NSCLC With EGFR L858R (FIRM Study)

P3.12.02 Real-World Outcomes in Patients With NSCLC and Leptomeningeal Disease

P3.12.03 Retrospective Analysis of Age, EGFR Mutation Type, and TP53 Co-Mutation on Survival Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer

P3.12.04 Taletrectinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models

P3.12.05 Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions - a Community Oncology Study

P3.12.06 Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC

P3.12.07 Rezivertinib in EGFR-Mutated NSCLC Patients With Cns Metastases: Cns Efficacy From Phase 3 RAZOR Study

P3.12.08 Weight Gain Induced by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small Cell Lung Cancer: A Meta-Analysis and a Meta-Regression Study

P3.12.09 Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study

P3.12.10 Adapting RECIST for Real-World Data: Independent Imaging Read Methodology Over Successive Treatments in a NSCLC Data Registry

P3.12.11 Aumolertinib Plus Chemotherapy as First - Line for Ps 2 - 3 Advanced NSCLC With EGFR Mutations: A Phase 2 Subgroup Analysis

P3.12.12 Clinical Pharmacologic Characteristics of Taletrectinib

P3.12.13 Long-Term Real-World Outcomes of Sotorasib in Second-Line and Beyond Treatment of KRAS G12C-Mutated Advanced NSCLC

P3.12.14 Clinical Effectiveness and Safety of Tepotinib in Patients From Germany With MET Exon14 Skipping NSCLC: A Case Series

P3.12.15 Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database

P3.12.16 Reduced Survival in Black Patients With EGFR-Mutant NSCLC

P3.12.17 A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations

P3.12.18 Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification And/Or Overexpression After Failure on EGFR-TKI: A Retrospective Study

P3.12.19 Optimizing Treatment Sequencing to Maximize Survival in ALK+ Advanced Non-Small Cell Lung Cancer: A Modeling Study

P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients

P3.12.21 Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

P3.12.22 A Phase II Study of Sunvozertinib Combined With Anlotinib in Treatment-Naïve NSCLC With EGFR Sensitive Mutations and Co-Mutations (WU-KONG32)

P3.12.23 Tepotinib Efficacy in Poor Performance Status and Elderly Patients With MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis

P3.12.24 Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-Small Cell Lung Cancer Patients

P3.12.25 First-Line HLX07 Plus Serplulimab With or Without Chemotherapy in Squamous Non-Small Cell Lung Cancer: A Phase 2 Study

P3.12.26 Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC

P3.12.27 Resistance Mechanisms of Novel Targeted Therapies to EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

P3.12.28 Association of PD-L1 Expression With Clinical Outcome in Advanced NSCLC With ALK Rearrangement

P3.12.29 Effectiveness and Treatment Patterns in Patients With First-Line 2G ALK TKI Across the Esme French Real-World Cohort

P3.12.30 Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features

P3.12.31 Rezivertinib in Advanced NSCLC Patients With EGFR T790M Mutation via Tissue/Plasma Samples: Pooled Analysis of 2 Clinical Studies

P3.12.32 Long-Term Survival Outcome After First-Line Osimertinib Monotherapy in Advanced/Metastatic NSCLC: Results From LC-SCRUM-Asia

P3.12.33 The Primary Endpoint Analysis of RELAY-Effusion; a Phase II Study of Ramucirumab Plus Erlotinib in EGFR-Mutated NSCLC With Pleural Effusion

P3.12.34 Real-World Study in Patients With ALK+ Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated With First-Line (1L) Lorlatinib

P3.12.35 Real-World Clinical Outcomes of Osimertinib in Patients With Recurrent EGFR Mutated Lung Adenocarcinoma: A Multicenter Study

P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan

P3.12.37 First-Line Lazertinib With or Without Local Ablative Radiotherapy in Oligo-Metastatic EGFR-Mutant NSCLC

P3.12.38 Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations

P3.12.39 Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China

P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION

P3.12.41 Factors Associated With Clinical Outcomes in Patients With HER2-Mutant NSCLC Treated With Sevabertinib (BAY 2927088)

P3.12.42 Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC

P3.12.43 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations

P3.12.44 A Retrospective Study of the Effect of Cumulative Smoking Dose on Clinical Course in People With EGFR-Mutated NSCLC Treated With Osimertinib

P3.12.45 Aumolertinib for Treatment-Naïve EGFR-Mutant NSCLC Patients With Brain Metastases: Updated Efficacy Data From the ARTISTRY

P3.12.46 Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT

P3.12.47 A Phase II Study of Sunvozertinib Combined With Chemotherapy in EGFR-TKIs Resistant EGFRm Advanced NSCLC Patients(WU-KONG36)

P3.12.48 Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

P3.12.49 Clinical Significance of a Genomic Screening Platform of Non-Small Cell Lung Cancer in Asia-Pacific: LC-SCRUM-AP

P3.12.50 A Prognostic Model Based on a Concurrent Gene Mutational Signature for EGFR Mutant NSCLC With TKI Treatments

P3.12.51 Patient-Derived Organoids as Preclinical Models for Drug Resistance in NSCLC

P3.12.52 Aumolertinib Plus Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation: A Single-Arm, Phase II Study

P3.12.53 High-Dose Furmonertinib Plus Bevacizumab in EGFR-Mutant NSCLC With CNS Metastases After Resistance to Third-Generation EGFR-TKIs

P3.12.54 Predicting Osimertinib-Induced Pneumonitis in EGFR-Mutated NSCLC Using Multi-Modal Machine Learning Model

P3.12.55 Efficacy of Vebreltinib in Advanced NSCLC Patients With MET Exon 14-Skipping: Post-Hoc Analysis of KUNPENG Study

P3.12.56 Medication Adherence to Osimertinib in Patients Diagnosed With Metastatic Non Small Cell Lung Cancer

P3.12.57 Phase I/II Study of FHND9041 in T790M-Positive Advanced NSCLC Patients Progressed After Prior EGFR-TKI Therapy

P3.12.58 Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors

P3.12.59 A Phase Ib/Ii Study of Vebreltinib Plus Tislelizumab in Patients With MET-Amplified and PD-L1-Positive Locally Advanced or Metastatic NSCLC

P3.12.60 The Combination of USP24-i-101-Astemizole Sensitizes the Cytotoxicity of Taxol and Gefitinib in Drug-Resistant Lung Cancer

P3.12.61 Retrospective Multicenter Study Within the German Network Genomic Medicine Lung Cancer on RET Fusions as Resistance in EGFR-Mutant Lung Cancer

P3.12.62 First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

P3.12.63 MTAPloss Is Frequent and Potentially Targetable With PRMT5 Inhibitors in Oncogene-Driven NSCL

P3.12.64 Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

P3.12.66 Overcoming Osimertinib Resistance in EGFR<+ NSCLC: PI3K Inhibitor Combined With Osimertinib Restores Drug Sensitivity

P3.12.67 Redefining Tolerability: A Head-To-Head IPD Toxicity Comparison of Amivantamab+Lazertinib vs Osimertinib+Chemotherapy in EGFR-Mutant NSCLC

P3.12.68 Regulating Autophagy Will Be a Potential Key Point in Overcoming EGFR TKI Resistance in Non-Small Cell Lung Cancer

P3.12.69 Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study

P3.12.70 Development of a Bispecific Antibody That Safely and Effectively Targets EGFR and B7H3 in NSCLC

P3.12.71 Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data

P3.12.72 FIN-EGFR/CNS: Real World Survival and Patient Characteristics of EGFR Mutated NSCLC Patients With Cns Metastases in Finland

P3.13.01 Effect of Patient Management System and Medical Resources on Outcomes of SCLC Treated With Chemo-ICI

P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma

P3.13.03 Proteomic Profiling of Small Cell Lung Cancer Patients Reveals Blood-Based Prognostic Proteins

P3.13.04 Consolidation Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC: A Multicentric Retrospective Analysis

P3.13.05 First-In-Human Study of 225Ac-ABD147 for SCLC and LCNEC Post-Chemotherapy: Pharmacokinetics, Biodistribution and Safety Insights

P3.13.06 Comprehensive Assessment of the Tumor Microenvironment of Resected Small Cell Lung Cancer

P3.13.07 Real-World Implementation of Immunotherapy for Stage III-IV Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021)

P3.13.08 Autologous Vax-NK/HCC Consolidation Therapy in ES-SCLC

P3.13.09 Surface Targeting Strategies to Overcome Heterogeneity Associated With Treatment Resistance in Small Cell Lung Cancer (SCLC)

P3.13.10 Real-World Outcomes of Prophylactic Cranial Irradiation (PCI) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the US

P3.13.11 HER2- and TROP2-Directed Antibody Drug Conjugates Show Potent Antitumor Activities in Small Cell Lung Cancer

P3.13.12 Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNEC Patients

P3.13.13 A Phase II Study of Vobramitamab Duocarmazine in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

P3.13.14 Lab Data-Based Prediction for Clinical Efficacy of Immunochemotherapy in ES-SCLC Using Statistical and Machine Learning Models

P3.13.15 First-Line Immunochemotherapy in ES-SCLC Patients With ECOG PS =2: Real-World Evidence From the ASTRUM-005R Trial

P3.13.16 Survival Outcomes With Carboplatin Versus Cisplatin and the Impact of COVID-19 on Platinum Choice in SCLC in the Netherlands

P3.13.17 A Comparative Analysis of TNM 8 and TNM 9 Classification Systems in Small Cell Lung Cancer

P3.13.18 Immunotherapy Pooled Analysis in 1L Extensive-Stage Small Cell Lung Cancer

P3.13.19 High Throughput Drug Screening for Small Cell Lung Cancer Based on Machine Learning and Organoid Platforms

P3.13.20 Integrative Spatial Analysis Reveals Ferroptosis Heterogeneity and Novel Therapeutic Vulnerabilities in Small Cell Lung Cancer

P3.13.21 Refining Patient Selection for Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Multicenter Cohort Study

P3.13.22 Efficacy and Safety of Surufatinib, Durvalumab in Combined With Chemotherapy as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

P3.13.23 Copy Number Gain of MYC-Paralogs Represents Proliferative Phenotype and Poor Prognosis in Resected Small Cell Lung Cancer

P3.13.24 Longitudinal Plasma Proteomics Identifies Predictive Biomarkers for Anti-PD-L1 Therapy in SCLC

P3.13.25 Comprehensive Immune Microenvironment Profile of EGFR-Mutant Non-Small Cell Lung Cancer Transformation Towards Small Cell Lung Cancer

P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes

P3.13.27 Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study

P3.13.28 Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis

P3.13.29 Somatostatin Receptor Expression and First-Line Somatostatin Analog Therapy: A Comparative Analysis in Thoracic Neuroendocrine Neoplasms

P3.13.30 Whole Exome Sequencing Analysis of Somatic Mutations in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

P3.13.31 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402

P3.13.32 Real-World Outcomes of Patients With Bronchopulmonary Neuroendocrine Tumors Treated With Lutetium Lu 177 DOTATATE (Lutathera)

P3.13.33 Clinical Outcomes and Single-Cell Map of Neoadjuvant Immunochemotherapyforstage Ii-Iiib LS-SCLC : A Real-World Study

P3.14.01 Global Trends in Asbestos Related Mesothelioma Mortality From 1990 to 2021

P3.14.02 Clinical Implications of BAP1 Status in Pleural Mesothelioma (PM)

P3.14.03 Loss of MHC Class I and II Defines an Immune Excluded Subtype in Pleural Mesothelioma

P3.14.04 High-Volume Surgical Centers for Pleural Mesothelioma Are Associated With Lower Perioperative Mortality

P3.14.05 Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatments

P3.14.06 Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey

P3.14.07 Recent Studies on Mesothelioma as a Model to Understand the Interaction of Gene and Environment (G X E)

P3.14.08 Genetically Defined Mouse Models of Malignant Pleural Mesothelioma Recapitulate Human MPM Phenotypes and Response to Therapy

P3.14.09 Sex-Based Differences in Mesothelioma: Insights From the ICO Cancer Registry

P3.14.10 Ultrasound Detection of Effusion and Neoplasia in Genetically Defined Mouse Models of Mesothelioma

P3.14.11 Real-World Outcomes and Toxicity of First-Line Dual Immunotherapy in Unresectable Pleural Mesothelioma

P3.14.12 Pseudo-Senescence Induced by Palbociclib Does Not Sensitize Pleural Mesothelioma Cells to Combinations With Classical Senolytics

P3.14.13 Sex and Histology Related Profile of Gut Microbiota (GM) in Pleural Mesothelioma (PM): Preliminary Results of a Prospective Observational Study

P3.14.14 Ten-Year Longitudinal Analysis of Mesothelioma Incidence: A Nationwide Cohort Study Based on the 2012 Korean Health Screening Registry

P3.14.15 Thymic Cancer in France: A Comprehensive Analysis of Incidence Based on French National Healthcare Data

P3.14.16 Prospects of Applyingconvolutional Neural Network Models for of Surgical Videos in Clinical Practice

P3.14.17 Oncological Outcomes of Complete Versus Limited Thymectomy in Stage I Thymic Epithelial Tumours

P3.14.18 The Role of Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis

P3.14.19 The Role of Tumors Size in Different Thymic Tumors Histology: Results Form the ESTS Thymic Database

P3.14.20 MTAP Deficiency in Thymic Epithelial Tumors

P3.14.21 Single-Nucleus RNA Sequencing Reveals Key Pathways and Prognostic Markers in Thymic Carcinoma

P3.14.22 Outcomes to Systemic Standard-Of-Care Therapies in Patients With MTAP-Deleted Advanced Non-Small Cell Lung Cancer

P3.14.23 The Mechanism of Immunotherapeutic Resistance in Pulmonary Sarcomatoid Carcinoma

P3.14.24 Tracheal Resection Surgery: Comparison of Continuous Vs. Interrupted Suture of the Membranous Wall in a Series of 162 Cases

P2.15 .01 Expedited Diagnostics Coordination Leads to Expedited Care in Advanced Stage Lung Cancer

P2.15 .02 Communication Needs of Patients With Advanced Lung Cancer Receiving Immunotherapy: Results of a Qualitative Study

P2.15 .03 Predictive Value of LIPI Score in the Response to Immunotherapy in Very Elderly Patients With Advanced Non-Small Cell Cancer

P2.15 .04 End-Of-Life Systemic Therapy and Survival in Metastatic Lung Cancer: A Territory-Wide Real-World Studyof 24,608 Patients

P2.15 .05 A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-Small Cell Lung Cancer: A Patient-Centered Approach

P2.15 .06 Best Practices and Process Variations of Lung Cancer Multi-Disciplinary Teams: Insights From Europe and Israel

P2.15 .07 Effect of Message Framing in a Digital Lung Cancer Screening Decision Navigation Intervention: A Three-Arm Randomized Controlled Trial

P2.15 .08 Effects of a Decision Support Intervention for Patients With Advanced Lung Cancer: RCT-Results and Document Analysis

P2.15 .09 Long-Term Survival in Malignant Pleural Effusion: Validation of the LENT and PROMISE Scores

P2.15 .10 Improving Patient-Reported Outcome Symptom Monitoring Using Bayesian Networks

P2.15 .11 Non-Cancer-Related Mortality in Lung Cancer Patients: The Role of Comorbidities in a 7-Year Retrospective Case-Control Study

P2.15 .12 Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer

P2.15 .13 Patient Self Management Education and Cancer Treatment Adherence in Low Middle Income Africa a Systematic Scoping Review

P2.15 .14 Improving Access and Recruitment to Clinical Trials for Lung Cancer Using the Lung I-Act Tool: A Mixed Methods Uk Wide Pilot Study

P2.15 .15 Impact of Palliative Care in Patients With Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis

P2.15 .16 ECMO as a Procedural Bridge for Malignant Airway Obstruction in Lung Cancer

P2.15 .17 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline

P2.15 .18 Quality of Life for Lung Cancer Survivors

P2.15 .19 Assessment of NSCLC Treatments and Correlation With Hypogonadism in Male Patients With NSCLC

P2.15 .20 Influence of Preoperative Mental Health on the Postoperative Outcome and Quality of Life After Anatomic Lung Resection

P2.15 .21 Feasibility and Preliminary Efficacy of Multimodal Prehabilitation in Patients With NSCLC Receiving Neoadjuvant Therapy

P2.15 .22 A Nutritional Strategy to Mitigate Toxicities and Optimize Dose Intensity in Patients With Lung Cancer: The Nutricare Study

P2.15 .23 Uncertainty in Illness, Symptom Severity and Hope in Advanced Lung Cancer Patients Undergoing Immunotherapy

P2.15 .24 A National Survey of Lung Cancer Survivorship Care at United States Cancer Centers From the American Cancer Society

P2.15 .25 Trilaciclib'S Myeloprotection in 1L Advanced Solid Tumors: Lung Cancer Data Analysis

P2.15 .26 Frequency of Adverse Events Reported Digitally by Patients With Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study

P2.15 .27 Symptom Screening Using the Patient-Generated Subjective Global Assessment Adds Value to Routine Clinical Review

P2.15 .28 Lorlatinib-Associated Dyslipidemia: A Multicenter, Retrospective Analysis and Implications for Future Cardiovascular Disease

P2.15 .29 Understanding the Psychosociological Burden of ALK+ NSCLC: Findings From the French Study «Living With ALK+ Cancer»

P2.15 .30 Impact of an Incidental Pulmonary Nodule Course Series on the Professional Development of Under-Resourced Multidisciplinary Teams

P2.15 .31 Integrating Biomarker Testing in Early-Stage Lung Cancer With a Nurse-Led Multidisciplinary Approach Using the 4R Oncology Model

P2.15 .32 Early Lung Cancer Detection and Multidisciplinary Care

P2.15 .33 A Comparative Study of the Significance of GPT-Enabled Counseling and Management of Pulmonary Nodules

P2.15 .34 Prompting and Medical Expertise Influence Large Language Model in Clinical Data Extraction: Findings From the APOLLO 11 Trial

P3.16.01 Lung Cancer Patients’ Understanding of and Involvement in Their Treatment and Care: Insights From a Global Patient Experience Survey

P3.16.02 Cancer Patients’ Advocacy and Policy Impact in Japan, How 3,623 Voices Halted a National Cost-Sharing Reform

P3.16.04 Lung Cancer Treatment in Brazil: The Gap Between Incorporation and Real-World Access

P3.16.05 Exploring Quality of Life in Oncogene Addicted NSCLC Patients and Their Caregivers

P3.16.06 The Saving Lungs Behind the Chair Model Is Increasing Lung Cancer Awareness in US Black Communities

P3.16.07 Canadian Action Plan for Lung Cancer - Patient Perspective

P3.16.08 Feasibility of Engaging Latino Individuals in a Lung Cancer Screening Study Through Mychart

P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers

P3.16.10 Co-Designing a Resource to Reduce Stigma in Lung Cancer Screening

P3.16.11 A Pulmón - Lunging It: Climbing Mountains and Breaking Barriers in Lung Cancer Advocacy

P3.16.12 Analysis of the Nationwide Database on the Penetration Rate of Lung Cancer Biomarker Tests in Japan

P3.16.13 Using Group Concept Mapping to Identify Research Priorities by Patient and Caregiver Stakeholders Affected by Lung Cancer

P3.16.14 The Influence of Deprivation on Lung Cancer Care Experiences in Urban, Rural, and Coastal Areas: A Qualitative IPA Study

P3.16.15 Giving Back - Co-Creation of Data Dashboard to Share Survey Results With Patients and Caregivers

P3.16.16 The Development of a Patient Education Lung Cancer Nodal Staging Video Toolkit: American Cancer Society National Lung Cancer Roundtable

P3.16.17 Understanding the Awareness of Treatment, Clinical Trails, Biomarkers and Unmet Needs of Chinese NSCLC Patients: A Mixed-Methods Study in China

P3.16.18 Beyond Clinical Outcomes: A Qualitative Exploration of Wellbeing Among People Living With Onco-Driven Lung Cancer

P3.16.19 Multilevel Assessment of ChatGPT-4O in Radiation Oncology for Lung Cancer Patient Education

P3.16.20 Improving Lung Cancer Screening Uptake in 20 Disadvantaged New York Counties: Early Findings From a Demonstration Project

P3.16.21 The Role of Neighborhood Deprivation in Lung Cancer Diagnosis and Treatment

P3.16.22 Frontline Insights in US Payer Barriers Impacting Patient Access and Participation in Comprehensive Lung Cancer Screening Programs

P3.16.23 Facilitators to Patient Advocacy Group-Led Engagement of Diverse, Community, Clinical Sites in Multiple Research Types

P1.17.01 Sociodemographic Factors in Access to Robotic-Assisted Oncologic Lung Resection, a United States (US) National Cancer Database Analysis

P1.17.02 Socioecological Factors Associated With Lung Cancer Clinical Trial Enrollment: Real-World California Cancer Registry Data

P1.17.03 Stage Iv Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Disparities and Outcomes: A Population-Based Study

P1.17.04 Prioritizing Lung Cancer Screening in Middle-Income Countries: A Feasibility-Need Framework to Guide Implementation

P1.17.05 Evolution of Neoadjuvant Treatment for Non Small Cell Lung Cancer (NSCLC) in Brazil: An Analysis From the Brazilian Lung Cancer Registry

P1.17.06 Who Gets a Biopsy? Disparities in Histological Confirmation and Survival Among Lung Cancer Patients

P1.17.07 Comparing Baseline Characteristics of NSCLC Patients Receiving Radiotherapy in Real-World Practice and Clinical Trials

P1.17.08 Routine Self-Administration of a Nursing Demographic Survey to Patients Starting TKIs Identifies At-Risk Individuals

P1.17.09 The Impact of Out-Of-Pocket Costs, Travel Distances and Clinic Visits on Quality of Life for Patients on TKIs

P1.17.10 Treating Without Guidelines: Management and Outcomes of Lung Cancer During Pregnancy

P1.17.11 Clinical and Molecular Characterization of Lung Cancer in Never-Smokers Identified Through an Incidental Nodule Program

P1.17.12 Unwarranted Variation in Lung Cancer Care in Perth, Western Australia: A Lung Cancer Clinical Quality Data Platform Report

P1.17.13 Biomarker Testing Timeliness for Patients With Lung Cancer

P1.17.14 Regional Disparities in Late-Stage Lung Cancer Outcomes in Sweden - Insights From Population-Based Data

P1.17.15 Social Vulnerability and Survival Outcomes in Stages I-II Lung Cancer: A Predictive Nomogram-Based Analysis

P1.17.16 Racial and Ethnic Disparities in Receipt of Guideline Concordant Treatment for Early-Stage NSCLC in Los Angeles County

P1.17.17 Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC

P1.17.18 Victorian Lung Cancer Registry Impacts on Multi-Disciplinary Lung Cancer Meeting Presentation

P1.17.19 Impact of Race and Ethnicity on the ENGAGE-Derived Lung Cancer Screening Recommendations: Implications for Risk Assessment

P1.17.20 Optimal Lung Cancer Outcomes for People From Rural and Remote Areas: An Overview of the Problem and a Research Program to Reduce Disparities

P1.17.21 Gender Disparities in Remote Patient Monitoring: Analysis From 973 Lung Cancer Patients Treated Across 42 Sites in France and Belgium

P1.17.22 Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

P1.17.23 Role of Lung Microbiome on Precise Diagnosis of Patients With Checkpoint Inhibitor Pneumonia: Result From a Prospective Cohort Study

P1.17.24 Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes

P1.17.25 Cost-Effectiveness of Initial Pan-TRK IHC Followed by RNA-NGS for NTRK Fusion Detection in Patients With NSCLC in China

P1.17.26 Evaluation of Large Language Models for Clinical Decision Support in Lung Cancer Treatment: ChatGPT-4.5 Vs. Deepresearch Vs. AvoMD

P1.17.27 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans

P1.17.28 Developing a Multifaceted Implementation Strategy to Increase Clinical Trial Accruals in Thoracic Oncology

P1.17.29 Access to Novel Therapies for the Treatment of NSCLC in 18 EU Member States

P1.17.30 Deep Learning-Based Lung Tumor Segmentation for Survival Prediction in NSCLC Patients

P1.17.31 Feasibility of Integrating Ai-Assisted Lung Cancer Screening in High Tuberculosis Burden Settings

P1.17.32 Comparing ChatGPT's and Google Gemini'S Responses to Lung Cancer Questions

P1.17.33 Addressing Educational Gaps in Lung Cancer Care: Insights Based on Global Practice Setting and Experience

P1.17.34 Assessing the Outcome of 10-Year Lung Cancer Survivors and the Necessity of Long-Term Postoperative Surveillance

P1.17.35 Patient Navigation and the Opportunity to Improve Experiences and Outcomes of Lung Cancer Care

P1.17.36 Perspectives on Health-Related Quality of Life Among Physicians and Patients With ALK-Positive NSCLC in China

P1.17.37 Providing Equal Access to Lung Cancer MDT Consultation Through Digital Innovation

P1.17.38 A Two-Layer MDT Model as the Standard of Care for Lung Cancer - a Good MDT Example With High-Volume Patients in Central Western China

P1.17.39 Clinical Predictive for Early Mortality in Stage IV Lung Cancer Without Targetable Mutations From Country With High Smoking Prevalence

P1.17.40 Impact of Remote MDT Through a Digital Platform: Insights From 70 Patient Follow-Ups

P1.17.41 Bridging Gaps in Lung Cancer Care: The Quantitative Impact of Inter-Hospital Remote MDT Consultations in China

P1.17.42 Canadian Consensus Recommendations for Multi-Disciplinary Team Meetings in Lung Cancer Care

P1.17.43 Association Between Pretreatment Emotional Distress and EGFR-TKI Therapeutic Response in EGFR-Mutant Non-Small Cell Cancer

P1.17.44 Multiomic Interaction Among Host and Tumor Immunity for Chemo De-Escalation. People Phase II Trial, First Line Pembrolizumab in Low PD-L1 NSCLC

P1.17.45 Multidisciplinary Digital Platform for Independent Adjudication of ILD/Pneumonitis Related to T-DXd Treatment

P1.17.46 The Best Care One-Lung Program; a Pathway for Lung Cancer Screening in Primary Care

P1.17.47 Safety and Efficiencies of Specialist Lung Cancer Nurse-Enabled Pulmonary Nodule Management: An Australian Demonstration

P1.17.48 Characteristics and Associated Survival of Patients Diagnosed With Non-Small Cell Lung Cancer in Western Kenya

P1.17.49 Real-World Outcomes With IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US

P1.17.50 Correlation Between Clinical and Pathological Stage in Resected NSCLC

P1.17.51 Real World Outcomes of Metastatic Mucinous Adenocarcinoma of Lung

P1.17.52 Real-World Treatment and Survival in KRASG12C-Mutated Locally Advanced/Metastatic Non-Small Cell Lung Cancer in England

P1.17.53 Real-World Experience With EGFR-Positive NSCLC in Resource-Limited Settings: A Decade-Long Single Center Study From Jordan

P1.17.54 Long-Term Outcomes From Pembrolizumab in Patients With Advanced PD-L1 =50% NSCLC and Poor PS: A Transformer-Based AI Approach

P1.17.55 Transforming Prognostication: A 5-Year Follow-Up Study to Unravel Prognostic Predictors Across Age Groups in NSCLC Using Transformer-Based AI

P1.17.56 Clinical Features and Outcomes of Lung Cancer in Young Patients

P1.17.57 Estimates of Clinical Endpoints in Matched Patients Between the French Cancer Cohort (FCC) and Durvalumab Stage III NSCLC Eap

P1.17.58 Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

P1.17.59 Real-World Uptake of Immunotherapy for Stage III-IV Non-Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021)

P1.17.60 Characterizing Multi-Timepoint Lung Cancer Progression With Dynamic Bayesian Network, Structural Equation Modeling and Random Forest Model

P1.17.61 Rebiopsy in Oncogene-Driven Lung Cancer: Real-World Practices in ALK, EGFR, and ROS1 Cohorts in the Australian AURORA Longitudinal Cohort Study

P1.17.62 Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA)

P1.17.63 Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis

P1.17.64 Acinar Cell Lung Carcinoma: A Unique Subtype of NSCLC Adenocarcinoma,Insights From the AACR Project Genie Database

P1.17.65 Age-Associated Incidence of Somatic Mutations and Survival Outcomes in Non-Small Cell Lung Cancer

P1.17.66 Impact of Concurrent Tissue and Liquid Comprehensive Genomic Profiling (CGP) on Receipt of First-Line (1L) Therapy in a NSCLC

P1.17.67 A Large-Scale Network Study on Impact of Immune Checkpoint Therapy in Metastatic Non-Small Cell Lung Cancer: The iCan mNSCLC Study-A-Thon

P1.17.68 Real-World Validation of Other Disease Morbidity After Lung Cancer Surgery Using a Japanese Database in Reference to JCOG0802/WJOG4607L

P1.17.69 A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care

P1.17.70 Clinicomolecular Characteristics and Treatment Patterns in Stage IV NSCLC: A Retrospective Study From Southwestern Ontario

P1.17.71 Treatment Changes Over 12 Months of Observation for ALK and EGFR-Positive NSCLC - Results From an Real-World Study

P1.17.72 Clinical and Dosimetric Predictors for Post-Radiotherapy Lung Cancer Recurrence: A Model for Resource-Limited Settings

P1.17.73 Misperception of Unintentional Weight Loss and Anorexia More Prevalent in Lung Cancer Among Other Solid Tumors in a Mexican Cohort

P1.17.74 Bridging Data Gaps in Brazilian Lung Cancer Surgery Care: The Evolution of the Brazilian Lung Cancer Registry (RBCP)

P1.17.75 Realizing Digital Transformation in Health: Findings From the TRANSITION Project

P1.17.76 Facilities and Workforce Available for Thoracic Oncologic Care and Research in Nigeria, a Low-Middle Income Country (LMIC)

P1.17.77 Lung Cancer Consensus: Uniting for a Healthier World

P1.17.78 Living Systematic Review Linked to Guidelines and Regulatory Approvals as a Treatment Decision Support Tool in NSCLC

P1.17.79 Assessing Radiotherapy Access and Patient Experience in Lung Cancer Treatment:A Survey on Financial and Logistical Challenges

P1.17.80 Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC) in Spain

P1.17.81 Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling

P1.17.82 Lung Cancer’s Price Tag: Escalating Hospitalization Costs in Brazil Over the Past Two Decades

P1.17.83 Implementation of Lung Cancer Screening by Family Physicians in the U.S.: Results of a National Survey

P3.18.01 Sex-Based Differences in STAS Positivity and Survival in Stage I Lung Adenocarcinoma: Is Female Prognosis Still Better Despite STAS?

P3.18.02 Sex-Based Differences in Immunotherapy Response via Blood Biomarkers in NSCLC: Interim Results From the ALICE Study

P3.18.03 Implementation Study of Lung Cancer Screening Combined With a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study

P3.18.04 MRDSEEKER (JCOG2111A): A Prospective Study to Evaluate MRD and Its Association With Prognosis in Curative-Intent NSCLC

P3.18.05 Enrollment Update for the CSP #2005 Phase III Veterans Affaris Lung Cancer Surgery or Stereotactic Radiotherapy Study [VALOR]

P3.18.06 Phase 1b Study of a Novel Fluorescent Imaging Agent, LS301, for Lung Cancer Surgery to Localize Tumors and Assess Margins

P3.18.07 Immunotherapy Combined With Radiotherapy as Neoadjuvant Therapy in Resectable NSCLC: A Single Arm, Phase II Clinical Study

P3.18.08 Alectinib as Adjuvant Therapy in Resected ALK-Positive NSCLC: A Prospective Multicenter Cohort Study in China

P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy

P3.18.10 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA3 EGFRm NSCLC With High Risk Factors

P3.18.11 Adding Certolizumab to Neoadjuvant Chemoimmunotherapy - Control of Immune-Related Adverse Events and Prevention of Surgical Delays

P3.18.12 ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study - Trial in Progress

P3.18.13 Atezolizumab +/- Tiragolumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer (AFT-57)

P3.18.14 Quick Start Durvalumab: A Phase II Pilot Study of Early Durvalumab Initiation Following Chemoradiation in Unresectable Stage II-III NSCLC

P3.18.15 Neoadjuvant and Adjuvant Chemoimmunotherapy in Resectable Stage II-IIIA NSCLC: Interim Results of a Prospective Cohort Study

P3.18.16 CROWD: Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab for Initially Unresectable Stage III NSCLC

P3.18.17 Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NeoRADjuvant)

P3.18.18 Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial

P3.18.19 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT2)

P3.18.20 PELAGOS: Integrating Surgery and Radiotherapy in EGFR-Mutant N3-Stage III NSCLC After Conversion Therapy

P3.18.21 Durvalumab (D) and Chemotherapy Followed by Either Surgery + D or Chemoradiotherapy + D in Borderline Resectable Stage III NSCLC

P3.18.22 TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

P3.18.23 Management of Synchronous Oligometastatic NSCLC With Surgical Resection of the Primary Tumor: Preliminary Results From the Prospective Trial

P3.18.24 A Multicenter, Open Label, Dual Cohort Study: The Efficacy and Safety of Vinorelbine Combined With a First-Line Treatment for Metastatic NSCLC

P3.18.25 Phase 2 Study of Carboplatin Plus Nab-Paclitaxel Rechallenge for NSCLC With Interstitial Lung Disease: TORG2442/CASTLE Study

P3.18.27 An Exploratory Clinical Study of TROP2 ADC SHR-A1921 Combined With Adebrelimab for Advanced NSCLC After Failure of First-line Standard Therapy

P3.18.28 KEYMAKER-U01 Substudy 01G: Pembrolizumab+Patritumab Deruxtecan±Chemotherapy in Previously Untreated Stage IV NSCLC

P3.18.29 NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma

P3.18.30 A Phase II Clinical Study of Tafolecimab Combined With Sintilimab in the Treatment of Advanced NSCLC Who Failed the Previous Immunotherapy

P3.18.31 Phase II Study of CBDCA + Nab-PTX + Tremelimumab+Durvalumab for TTF-1 Negative Advanced non-sq NSCLC (WJOG17223L, TURNING)

P3.18.32 Tislelizumab Combined With Bevacizumab and Nab-Paclitaxel as Second-Line Therapy for PD-1/L1 Inhibitor-Resistant Advanced NSCLC

P3.18.33 Intrapleural Anti-PD-1 Antibody for the Treatment of Advanced Non-Small Cell Lung Cancer With Malignant Pleural Effusion

P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC

P3.18.35 ARTEMIDE-Lung02: A Phase 3 Global Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for 1L Metastatic Squamous NSCLC

P3.18.36 Peripheral Immune and Hormonal Signatures Associated With Sex Differences in NSCLC Response to Checkpoint Inhibition

P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 Tps =50%

P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%

P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors

P3.18.40 KRAS Peptide Vaccine Combined With Chemotherapy, Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer

P3.18.41 A Phase II Study of Second-Line Cadonilimab, Bevacizumab and Docetaxel in Patients With Advanced NSCLC

P3.18.42 Camrelizumab Combined With Chemotherapy and Local Consolidative Therapy for Untreated Oligometastatic NSCLC With PD-L1 Expression <50%

P3.18.43 A Phase II Study of IDH1 Inhibitor Combined With Serplulimab and Docetaxel in Previously Treated Advanced NSCLC (ChiCTR2400086196)

P3.18.44 Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Patients With Non-Small Cell Cancer

P3.18.45 A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitior for Treatment Naïve or Acquired Resistant to Immunology NSCLC

P3.18.46 Ivonescimab Plus Platinum-Doublet Chemotherapy as First-Line Therapy for Locally Advanced/Metastatic SMARCA4-Deficient NSCLC

P3.18.47 ATTEND: Randomized Phase III Trial of Tislelizumab and Chemotherapy With or Without Diphenhydramine in Advanced Non-Small Cell Lung Cancer

P3.18.48 Phase II Clinical Trial of Trilaciclib in Combination With PD-1 Inhibitor and Chemotherapy as First-Line Treatment for (NSCLC)

P3.18.49 Efficacy and Safety of Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy

P3.18.50 Induction Tislelizumab With Chemotherapy Followed by Surgery and Radiotherapy in Stage Ill-N3 Unresectable NSCLC (HURRICANE)

P3.18.51 Anlotinib Combined With PD-1 Blockade and Platinum Doublet Chemotherapy for PSC as First Line Treatment

P3.18.52 Phase 3 Trial ResQ201A of NAI Plus Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced or Metastatic NSCLC Resistant to ICI Therapy

P3.18.53 Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy

P3.18.54 Increasing the Dosing Interval of Osimertinib in Patients With EGFR-Mutated Advanced NSCLC (OSI-SAVE Study Design)

P3.18.55 A Phase II Study of Repotrectinib in ROS1-Positive Non-Small Cell Lung Cancer Patients With Active Brain Metastasis - REPOSE

P3.18.56 EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study (ERIS): A National Phase III Trial From the Swedish Lung Cancer Study Group

P3.18.57 Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

P3.18.58 Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 Tps <50% NSCLC (DESTINY-Lung06)

P3.18.59 Resistance Mechanisms and Sequential Therapies Following 1St Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)

P3.18.60 The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome

P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC

P3.18.62 TRUST-III: Phase 3 Head-To-Head Study of Taletrectinib vs Crizotinib in Patients With ROS1+ Non-Small Cell Lung Cancer

P3.18.63 Phase 1 Study of FHND5071, a Novel Selective RET Inhibitor, in RET Fusion-Positive Advanced NSCLC

P3.18.64 Phase 1 Study to Evaluate the Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous NSCLC

P3.18.65 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC

P3.18.66 Preliminary Safety and PK of the MET-TKI Do-2 in Advanced Solid Tumors With MET Aberrations: Phase I Study

P3.18.67 First-In-Human Phase I/II Trial of PFL-002/VERT-002 in Locally Advanced or Metastatic Solid Tumors Including NSCLC With MET Alterations

P3.18.68 First-In-Human Trial of PFL-241/STX-241 in Patients With Locally Advanced or Metastatic NSCLC Resistant to EGFR Tyrosine Kinase Inhibitors

P3.18.69 Efficacy and Safety of Befotertinib Plus Icotinib in Advanced NSCLC With Uncommon EGFR Mutations: A Phase II Study (Icombine)

P3.18.70 Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients

P3.18.71 CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors With Homozygous MTAP Deletion

P3.18.72 Liquid Biopsy Guided Addition of Chemotherapy With TKI in Advanced EGFR Mutated NSCLC (LiquiACT)

P3.18.73 A Phase 1b/2 Study of Gocatamig and Ifinatamab Deruxtecan for Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

P3.18.74 BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)

P3.18.75 Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC

P3.18.76 Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer

P3.18.77 Efficacy and Safety of Adebrelimab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH)

P3.18.78 A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer

P3.18.79 Contralateral Esophageal-Sparing Technique Reduces High-Grade Esophagitis in Locally Advanced Small Cell Lung Cancer

P3.18.80 A Phase 3 Study of Sacituzumab Govitecan in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer

P3.18.81 A Phase II Study of First-Line Sintilimab Combined With Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM

P3.18.82 Towards Harmonization of Clinical Care and Promoting Research for Thymic Epithelial Tumors: THETIS (THymic Cancers NETwork in Switzerland)

P3.18.83 Efficacy and Safety of Ivonescimab Plus Chemotherapy for Recurrent/Metastatic Thymic Carcinoma: A Phase II Study (iThyme)

P3.18.84 A Randomized Comparative Effectiveness Trial of Perioperative Physical Activity in Older Adults With Lung Cancer and Their Family Caregivers

P3.18.85 A Personalized Nutrition and Physical Exercise Intervention to Enhance Early-Stage NSCLC Outcomes: The STARLighT Study

P3.18.86 Efbemalenograstim Alpha Prophylaxis for Intermediate-Risk FN Chemotherapy in NSCLC: A Multicenter Exploratory Study

EP.18.01 The Beneficial Value of 18F FDG PET/CT in the Follow-Up of Stage III Non-Small Cell Lung Cancer Patients (NVALT31-PET Study)

EP.18.02 Multicenter, Prospective Study on the Precise Diagnosis and Treatment of Shape-Sensing Robotic-Assisted Bronchoscopy

EP.18.03 Neoadjuvant Toripalimab for Stage Ii-Iiib Resectable NSCLC With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

EP.18.04 CLOG-0004 Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

EP.18.05 Tislelizumab Combined With Low-Dose Chemotherapy in Previously Treated Advanced Squamous NSCLC

EP.18.06 ML44840: A Multicenter Prospective Cohort Study of the Patient-Reported Outcomes in Chinese Patients With ALK+ Advanced NSCLC

EP.18.07 Aumolertinib Combined With Lomustine as First-Line Treatment for EGFR-Mutant NSCLC Patients With Brain Metastasis

EP.18.08 Adebrelimab as Consolidation Therapy in Limited-Stage Small Cell Lung Cancer After Hyperfractionatedradiotherapy Combined With Chemotherapy

EP.18.09 Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer

EP.18.10 Phase II Study: Efficacy and Biomarker Exploration of Anlotinib Plus Penpulimab in ES-SCLC After Failure of Platinum-Based Chemotherapy